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Abstract 
Since the discovery of mesoporous silica nanoparticles (MSNs) by Mobil’s researchers in 1992, it 
has aroused keen interest for its application in catalysis, adsorbent, and many more owing to its 
structural characteristics of high surface area, possibility of surface functionalization and adjustable 
pore size. It was in the last decade when MSNs were first reported for its application in drug 
delivery and since then researchers are exploring possibilities of MSNs to resolve the challenges in 
the pharmaceutical sector. 
More than 40% of pharmaceutical drug candidates emerging from high throughput screening 
process are hydrophobic possessing low aqueous solubility and hence low bioavailability. These 
drug molecules are highly potent but, cannot be formulated as an effective formulation owing to its 
low aqueous solubility which hinders its clinical application. This raises a huge challenge for 
pharmaceutical scientists to enhance the aqueous solubility of hydrophobic drugs. Reducing the 
drug particle size can enhance the solubility according to the Ostwald–Freundlich equation. 
However, it has been difficult to downsize the drug particle below 20 nm with the existing 
technologies, a regime in which a dramatic increase in solubility is expected.   
This research work seeks to overcome the limitations by enhancing aqueous solubility of 
hydrophobic drug molecules using MSNs. A simple and novel method have been developed 
wherein the pore size of MSNs can be systematically adjusted in a stepwise manner at step 
precision of angstrom scale to obtain a series of MSNs with controllable pore size (1-10 nm). By 
loading drug molecules inside the pores of MSNs, the drug particle sizes can be confined to the pore 
size. We hypothesize that, there exists an optimized pore size for a given hydrophobic drug 
molecule which would display highest solubility. We successfully demonstrated that there exists an 
optimized MSN pore size displaying highest aqueous solubility by studying pore size – solubility 
relationship for a given hydrophobic drug molecule.  
In this research work, we attempted to enhance the cytotoxicity of the hydrophobic anticancer drug 
using MSNs as carrier system. The most preferred strategy for targeting cancer cells and enhancing 
anticancer drug’s cytotoxicity is by designing the carrier system with positive surface charge. 
Positively charged carrier systems are reported to demonstrate high cellular uptake by cancer cells 
as cancer cells are negatively charged. However, bare positively charged carriers display toxicity, 
raising concern for its application.  
To understand the parameters influencing the cellular uptake of MSNs in enhancing the anticancer 
drug’s cytotoxicity, we synthesized MSNs with different surface functionalities. Surface 
functionalization was performed on MSNs to study the effect of surface charge and hydrophobicity 
by encapsulating anticancer drug in the pores of MSNs. We found that, the negatively charged 
MSNs have faster drug release and low cellular uptake while positively charged MSNs showed 
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relatively slower release and high cellular uptake. However, the anticancer activity displayed by 
negatively charged MSNs is similar to the positively charged MSNs. The similar anticancer activity 
could be attributed to the effect of cellular uptake and in vitro release. The hydrophobic MSNs did 
not enhance the anticancer activity owing to its hydrophobic surface leading to poor wetting effect. 
These results were further confirmed by selecting another hydrophobic drug molecule which 
demonstrated enhancement in drug solubility and drug release by negatively charged MSNs 
compared to the positively charged MSNs and hydrophobic MSNs. The findings from this work 
hints towards a new approach in designing carrier system for cancer treatment.  
The research work in this thesis contributes to new strategies to achieve solubility enhancement for 
hydrophobic drugs and designing carrier system to enhance cytotoxicity of hydrophobic anticancer 
drugs promising their application in the pharmaceutical field. 
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Chapter 1  
Introduction 
 
1.1 Background 
 
The human kind has always been struggling to combat the diseases with the help of medicines. 
Most of the drugs used as medicines for treating these diseases have high side effects and lack 
patient compliance necessitating the requirement for discovery of potent, safe drug and effective 
drug carrier system. However, more than 40% of drugs emerging from high throughput screening 
process are hydrophobic and highly potent but, possess low aqueous solubility. The low aqueous 
solubility not only lowers the bioavailability but also hinders its clinical application. This raises a 
huge challenge for pharmaceutical scientists to find solution to enhance solubility of these 
hydrophobic drugs. Till date several strategies have been developed to address this issue which 
comprises of conventional and nanotechnological approaches but, with limited success. Of the 
strategies developed, drug particle size reduction has been proposed to be the most promising 
strategy based on Ostwald–Freundlich equation. However, the drug particle size cannot be reduced 
below 20 nm, a regime in which a dramatic increase in solubility is expected.  Thus, the quest to 
find an appropriate method for solubility enhancement of hydrophobic drugs such as anticancer 
drug still persists. 
 
Recently inorganic mesoporous silica nanoparticles (MSNs) have been proposed to address this 
issue owing to its structural characteristics such as high surface area, possibility of surface 
modification, adjustable pore size to name a few. By confining the drug molecules in the pores of 
MSNs with pore size 1-10 nm, the drug particle size can be reduced which would help to enhance 
the drug solubility. However, one needs to find an optimized pore size for a given drug to 
encapsulate it in the pores and achieve highest solubility. To achieve this aim, we need to find a 
technique which can precisely control the pore size adjustment at angstrom scale. This study was 
further postulated using a model hydrophobic anticancer drug molecule, Curcumin.  
 
Cancer treatment requires delivering anticancer drugs to cancerous cells using appropriate carrier 
system. As cancer cells are negatively charged, designing positively charged carrier system is the 
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most preferred strategy. However, bare positively charged carrier system pose cytotoxic activity 
raising concern for its application. As MSNs are reported to enhance solubility of hydrophobic 
drugs, it can be selected as the carrier system owing to its ability of surface functionalization. MSNs 
with different surface functionalization can be evaluated to study its efficacy as drug carrier in 
enhancing cytotoxicity of encapsulated hydrophobic anticancer drug.   
 
 
1.2 Aim of the research and its Significance 
 
As the hydrophobic drugs (such as anticancer drugs) possess drawback of low aqueous solubility, it 
is important to enhance their solubility using a general strategy. Most of the anticancer drugs are 
hydrophobic in nature with low aqueous solubility and this technique could help in cancer 
treatment. Carrier system plays an important role in delivering the drugs to its specific site. 
Especially, in cancer as the cancer cells are negatively charged, positively charged carrier systems 
are more preferred but pose cytotoxic activity. Positively charged mesoporous silica nanoparticles 
are studied as carrier system for cancer disease but face toxicity issues owing to the agents used for 
their surface functionalization. Hence, it is important to study the influence of surface 
functionalization in proposing mesoporous silica nanoparticles as carrier system.   
 
The specific objectives of this research are: 
1. To develop a technique for solubility enhancement by controlling the pore size of 
mesoporous silica nanoparticles at angstrom scale to find an optimized pore size for a given 
hydrophobic drug.  
2. To study the efficacy of mesoporous silica nanoparticles as carrier system for enhancing 
cytotoxicity of anticancer drugs. 
3. To study the influence of surface functionalized mesoporous silica nanoparticles on drug 
solubility and drug release. 
4. To study the influence of surface functionalized mesoporous silica nanoparticles on 
cytotoxicity of anticancer drugs. 
 
This research would address the challenge of enhancing the solubility of hydrophobic drugs by 
proposing a novel method to control the pore size of mesoporous silica nanoparticles at angstrom 
scale. As this strategy could be applied to all hydrophobic drugs, it would help significantly towards 
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the development of effective drug delivery system. The findings generated by encapsulating 
hydrophobic anticancer drug in mesoporous silica nanoparticles and carefully evaluating the 
influence of surface functionalization on drug solubility, drug release and cytotoxicity better 
understanding and new strategies could be developed for cancer treatment. 
 
1.3 Structure of the thesis 
 
Chapter 1 Introduction 
 
A brief overview of the background of this research work, including aims and significance are 
presented.  
 
Chapter 2 Literature Review 
 
A literature review focusing on solubility enhancement techniques is presented. A detailed review 
of the contributions made by the mesoporous silica nanoparticles as drug delivery system including 
effect of pore size, surface functionalization and cytotoxicity is presented.   
 
Chapter 3 Research Methodology 
 
The systematic approach in this research work is presented.   
 
Chapter 4 Stepwise Pore Size Reduction of Ordered Nanoporous Silica Materials at 
Angstrom Precision   
 
In this chapter we report, a novel technique for controlling pore size of mesoporous silica 
nanoparticles at angstrom scale and demonstrating its application for solubility enhancement of 
hydrophobic drug. This chapter was published in Journal of the American Chemical Society, 2013, 
135, 8444-8447.  
 
Chapter 5 Mesoporous Silica Nanoparticles Enhance the Cytotoxicity of Curcumin 
 
In this chapter, mesoporous silica nanoparticles are studied as drug carrier system by encapsulating 
hydrophobic anticancer drug in it and studied for its cytotoxicity. Encapsulation of drug in 
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mesoporous silica nanoparticle resulted in cytotoxicity enhancement compared to the pure drug 
signifying its advantage as drug carrier system. This chapter was published in RSC Advances, 2014, 
4(2), 709-712. 
 
Chapter 6 Effect of Surface Functionality of Silica Nanoparticles on Cellular Uptake and 
Cytotoxicity 
 
This chapter is continuation of chapter 5 where in mesoporous silica nanoparticles with different 
surface chemistry (surface charge and hydrophobicity) are synthesized and studied for its influence 
on drug release, cytotoxicity by encapsulating the above hydrophobic anticancer drug. Detailed 
investigation is performed to understand the effect of surface chemistry on anticancer activity using 
anticancer cell line. This chapter is submitted to Molecular Pharmaceutics, 2014. 
 
Chapter 7 Modulating in vitro Release and Solubility of Griseofulvin Using Functionalised 
Mesoporous Silica Nanoparticles 
 
To confirm the finding from chapter 6 emphasizing the role of surface functionality, the 
mesoporous silica nanoparticles with different surface chemistry (surface charge and 
hydrophobicity) were studied for their influence on drug solubility and drug release using a 
hydrophobic antifungal drug. This chapter is submitted to Journal of Colloid and Interface 
Sciences, 2014. 
 
Chapter 8 Conclusions and Recommendations 
 
Conclusion and major contributions of this work are highlighted and recommendations for future 
works are presented. 
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Chapter 2  
Literature Review 
2.1 Hydrophobic drugs and its dilemma  
 
More than 40% of newer drug molecules emerging from high-throughput screening for treating 
diseases such as cancer (anti-cancer drugs such as Paclitaxel, Camptothecin, etc.), fungal infection 
(anti-fungal drugs such as Amphotericin B, Itraconazole, Griseofulvin etc.), anxiety (anti-anxiety 
drugs such as Alprazolam, Diazepam, Lorazepam etc.), diabetes (anti-diabetic drugs such as 
Glibenclamide, Glipizide, etc.), inflammation (anti-inflammatory drugs such as Ibuprofen, 
Naproxen, Diclofenac etc), etc. are hydrophobic in nature possessing poor aqueous solubility, 
resulting in low bioavailability and reduced patient compliance requiring to have frequent 
administration of drug.
1,2
 These characteristics not only create an obstacle in drug formulation 
development but also delays their clinical applications.
3
 Hence there is a need to address these 
concerns by developing efficient solubility enhancement method and designing appropriate drug 
carrier system.  
 
2.1.1 Enhancement of drug solubility – Conventional approach 
 
To overcome the poor aqueous solubility of such hydrophobic drugs, conventional strategies 
such as salt formation, complexation, use of co-solvents, etc. are employed.  
 
As most of the active drug molecules have poor aqueous solubility, its salt forms were 
synthesized. This salt form of the drug molecules not only retained the pharmacological activity of 
the drug but also enhanced its aqueous solubility. The most common drug-salt form comprise of 
chlorides, carbonate, maleate, citrate etc. Many products with drug-salt form as active constituent 
have been commercially synthesized such as Diclofenac sodium, chlorphenaramine maleate, etc.
4
  
 
Complexation technique employs conjugation of drug molecules within the cavity of 
cyclodextrins (CD). Various kinds of cyclodextrin are currently available such as α-CD, β-CD, -
CD, Hydroxypropyl β-CD, etc. CD were discovered in 1891 however it’s industrial application 
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begun in 1970s. Till date several product have been developed using CD to enhance solubility for 
drugs such as Piroxicam, Itraconazole, Hydrocortisone, etc.
5
 
 
 Co-solvents are mixtures of water and one or more water miscible solvents used to create a 
solution with enhanced solubility for hydrophobic drug molecules. The most commonly used co-
solvents used are propylene glycol, ethanol, glycerin, polyethylene glycol, and Dimethylsulfoxide 
(DMSO), etc.
4
  
 
The conventional strategies employed face the problems of precipitation, toxicity and altered 
pharmacological activity.
3,6,7
 Also, these techniques are not applicable to all the drug molecules 
which results in exploring effective techniques to enhance the drug solubility.  
 
2.1.2     Relationship between solubility and drug particle size 
 
Reducing micron-sized drug particles to the nano range or sub-100 nm range is important as 
it leads to an increase in saturation solubility and dissolution velocity because of the change in 
physicochemical properties which is the basis of nanotechnology and explained by Ostwald-
Freundlich and Noyes-Whitney equations respectively.
3,8
  
 
In general, the solubility of a particle is related to both its bulk molecular property and 
interfacial property, which can be described by the Ostwald-Freundlich equation (Eq. 1) according 
to which a decrease in particle size (r) results in an increase in saturation solubility of the drug.
9
  
 
S/S0 = exp (2M / rρRT) ------------------------------------- Eq. 1 
 
where S is the solubility of a spherical particle of radius r,  
S0 is the equilibrium solubility,  
R is the universal gas constant,  
T is the temperature,  
M is the molecular weight,  
ρ is the density and  
  is the solid-liquid interfacial tension.  
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In the case of hydrophobic drug molecule - curcumin, Eq. (1) can be rewritten as (assuming 
T = 298 K, M = 368 g/mol, ρ = 1.0 g/cm3) 
 
S/S0 = exp (0.3 / r) ------------------------------------------- Eq. 2 
 
To semi-quantitatively explain the S-r relationship, we arbitrarily define rc as the critical 
radius where S/S0 = 2. Because there is no method available to precisely determine , the value of  
is also arbitrarily set in a common range of 5-20 mN/m. As shown in Fig. 1, it can be seen that in 
order to achieve S/S0 = 2, rc is 2.2, 4.3 and 8.7 nm when  is adjusted to 5, 10 and 20 mN/m, 
respectively. Moreover, it is also clearly seen that S increases more significantly when r < rc. 
Therefore, in order to significantly enhance the solubility of hydrophobic drugs, it is extremely 
important to restrict their particle size in the range of 1-10 nm, especially for drugs with low   
values. 
 
Fig. 2.1 Influence of drug particle size on solubility at different interfacial tensions based on 
Ostwald-Freundlich equation for curcumin. 
 
On size reduction, the surface area of a particle increases drastically, thereby a tremendous rise 
in dissolution velocity is observed as given by the modified Noyes-Whitney equation
10
 (Eq. 3) 
describing the dissolution velocity 
 
-dM/dt = DA/h (CS - CB) ---------------------------------- Eq. 3 
 
where M is mass of drug dissolved in time t,  
D is diffusion coefficient of drug in medium,  
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A is surface area,  
h is thickness of stagnant film layer,  
CS is saturation solubility at drug-media interface and CB is drug concentration in bulk medium.  
 
On careful evaluation of the parameters involved in the above equation with respect to their 
role in dissolution it can be seen that surface area and solubility can lead to significant enhancement 
in dissolution velocity of the drug. 
 
2.1.3     Relationship between solubility and surface charge 
 
For a given drug, its surface charge can be defined by its dissociation constant which plays 
an important role in influencing its solubility. Most of the drugs are weak electrolytes and have 
tendency to undergo ionisation in solution. Drugs are more soluble in its ionised state while reflect 
poor solubility in its unionised state. The degree of drug ionisation is governed by two factors – 
dissociation constant and pH of the medium.  
 
The equilibrium achieved by weakly acidic drug, HA in solution can be represented as: 
HA ⇌ H+ + A-  ---------------------------------- Eq. 4 
Similarly the protonation of weakly basic drug, B can be represented as: 
B + H
+
 ⇌ BH+ ---------------------------------- Eq. 5 
 
Solving the above equilibrium reactions we are able to obtain following equations which are 
termed as Henderson-Hasselbalch equation and describe the relationship between the dissociation 
constant of the drug and the pH of the medium. 
 
For weakly acidic drugs: pKa = pH + log10 [HA] / [A
-
] --------------------------------- Eq. 6 
 
For weakly basic drugs:  pKb = pH + log10 [BH
+
] / [B] --------------------------------- Eq. 7 
 
The symbol pKa is used to represent the negative logarithm of the acid dissociation constant, 
Ka in an analogous way where pH is used to represent the negative logarithm of the hydrogen ion 
concentration. Similarly, pKb represents the negative logarithm of the basic dissociation constant, 
Kb. 
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An increase in solubility can be observed with increasing pH for weakly acidic drugs as the 
concentration of ionized species is higher compared to that of unionized species. Conversely, 
increase in solubility can be observed for weakly basic drugs with decrease in pH. This relationship 
between drug’s dissociation constant and pH helps to understand the solubility of drug and its effect 
on bioavailability.
11
   
 
2.1.4      Enhancement of drug solubility – Nanotechnology approach  
 
With the need to enhance the drug solubility, drug particle size reduction is seen as the most 
promising approach leading to new era of nanotechnology. Nanotechnology involves ‘bottom up’ 
and ‘top down’ (also known as nanosizing) approaches to achieve solubility enhancement.8,12  
 
The bottom up approach involves a controlled precipitation process in which the drug is 
dissolved in a solvent and this solvent solution is then added to a non-solvent medium resulting in 
precipitation to form crystalline or amorphous drug particles. There are various controlled drug 
precipitation process wherein we can obtain water-insoluble colorants in colloid-disperse form 
(patented process by BASF)
13
, cold-water dispersible powders such as carotenoid preparation 
(patented process by BASF)
14,15
, and generation of amorphous drug particles which are marketed by 
the name of Nanomorph. There are few more techniques such as highgravity controlled 
precipitation technology, sonocrystallization etc.  which helps in obtaining drug crystals for 
solubility enhancement.
8
 The main disadvantage of bottom-up approach is the removal of organic 
solvent used in the process. Hence, this approach is not the preferred approach for solubility 
enhancement.   
 
 Top-down approach includes techniques such as micronization.
2,16
 Micronization technique 
represents processes such as milling and homogenization. The most preferred milling process is the 
wet milling where in the drug is dispersed in surfactant solution or a stabilizer solution and 
subjected to milling process. Wet milling can be conducted using either high energy or low energy. 
A low energy wet milling processes is pearl mill which can reduce the drug particle size range of 
0.2 – 0.4 mm.2 The low energy wet milling takes longer duration of upto several days for drug 
particle size reduction. Alternatively, high energy wet milling processes can reduce the drug particle 
in 30-120 mins making it industrially favourable. Nanocrystal process is based on such high 
energy wet milling process.
12
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Homogenization process involves drug attrition to small size under high energy. The sample 
preparation is similar to the wet milling process which involves preparation of dispersion medium 
containing drug and stabiliser/ surfactant.
17
 The advantages of homogenization process is reduction 
in time, reduced microbiological issues and less contamination compared to the milling process.
18
 
Nanosuspension formulated using homogenization process helps in increasing the chemical stability 
of the drug which was demonstrated using Omeprazole as the drug molecule. Omeprazole 
nanosuspension exhibited excellent stability and there was no change in the drug content or color as 
compared to the Omeparzole suspension prepared by conventional technique.
19
  
 
The major drawback of top-down approach is that it is time and energy consuming, the drug 
particle size achieved is larger than 100nm and drug particles are prone to degradation due to 
mechanical stress involved in the process and have a tendency to agglomerate.
20
 Also, specially 
designed equipments are required to meet the demands of high energy wet milling process.
12
 The 
nanosizing technique has been successfully applied for a few hydrophobic drugs to improve their 
dissolution rate in vitro and their bioavailability.
21
 The complete list of drug molecules approved by 
FDA for commercial sale is listed in the table 1 below. 
Company Trade Name Drug FDA approval 
date 
Description Technology Advantage 
Wyeth 
Pharmaceuticals 
Rapamune  Sirolimus Aug. 2000 Tablet Wet milling Improved 
bioavailability, 
dose 
proportionality, 
absorption 
variability 
Merck Emend Aprepitant Mar. 2003 Capsule Wet milling Eliminating food 
effect 
Abbott labs TRICOR Fenofibrate Dec. 2004 Tablet Wet milling Eliminating 
fed/fast effect 
Par 
Pharmaceuticals 
Megace ES Megestrol  
acetate 
Jul. 2005 Oral 
suspension 
Wet milling Rapid onset of 
action, lower 
dosing regimen 
Nucryst 
Pharmaceuticals 
NPI 32101 Silver Jul. 2007 Topical cream Magnetron 
sputtering 
Enhanced 
antimicrobial 
activity 
Janssen 
Pharmaceuticals 
Invega 
Sustenna 
Paliperidone 
Palmitate 
Jul. 2009 Extended 
release 
injectable 
suspension 
Wet milling Reducing risk of 
relapse 
Table 2.1. Commercialized Nanocrystal based Drug Formulation (reproduced from ref. 4) 
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The drug particle size achieved by the existing nanotechnology approach is still above 100 
nm and based on Ostwald-Freundlich equation, if we are able to reduce the drug particle size below 
50 or 10 nm, we may be able to observe drastic increase in solubility. Thus the limited success 
achieved to date with the nanotechnology approach, demands the development of a general strategy 
to downsize the drug particles to sub-nano scale or even smaller, to further increase the solubility 
and bioavailability of hydrophobic drugs. 
 
2.1.5     Drug Delivery Systems 
 
A drug delivery system (DDS) is a two component system comprising of ‘Drug’ and ‘Delivery 
system’. The first component of DDS – Drug is defined as “a substance intended for use in the 
diagnosis, cure, mitigation, treatment, or prevention of disease” according to U.S. FDA.22 However, 
most of the drugs cannot be administered in the body directly as they have certain physicochemical 
limitations such as low aqueous solubility, poor permeability, unstable to light, unpalatability to 
name a few. Hence, it is important to select or design an appropriate delivery system which would 
help in improving the drug efficacy and safety. 
 
The second component of DDS – Delivery system is defined as a formulation or a device that 
enables the introduction of a therapeutic substance or drug in the body improving its efficacy and 
safety by controlling the rate, time, and place of drug release in the body.
23
 To cater the above 
requirement, various delivery systems such as tablets, capsules, suspensions, injections, etc. had 
been developed. For example, Ibuprofen – a well-known drug for treating pain and inflammation 
has low aqueous solubility and bitter taste
24
 and hence it is administered in the form of tablet or 
suspension to overcome its limitations. The solubility of Ibuprofen in the tablet or suspension can 
be enhanced by one of the approaches such as reducing its particle size by top-down or bottom-up 
technique or by using an inclusion complex of ibuprofen and cyclodextrin or by obtaining 
microsphere of Ibuprofen and polymer in the formulations.  
 
2.1.6     Current Drug Carrier systems 
 
The drug particle size obtained using either of the nanotechnological approach needs to be 
administered to the patients using an appropriate delivery system. Moreover, the drug carrier system 
used in DDS should have ideal features such as bioinertness, biodegradability, physicochemical and 
structural stability, lack of immunogenicity, cellular targetability, programmability, zero premature 
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drug leakage until it reaches the target cell, facile synthesis process with high reproducibility.
23
 In 
quest of developing such an ideal DDS several novel systems such as liposomes, dendrimers, 
polymeric nanoparticles, solid dispersions, microemulsions, etc. have been developed. However, 
these systems possess drawbacks such as low drug loading, poor stability, tedious synthesis process, 
etc.  
In comparison to the above organic based DDS, inorganic mesoporous silica nanoparticles 
have attracted huge research interest in the fields of catalysis and DDS.
25
 Since the first study, it has 
attracted enormous interest in drug delivery field and several studies have been conducted to study 
its efficacy and found to be almost fulfilling the ideal DDS characteristics.   
 
2.2       Mesoporous silica materials 
 
Mesoporous silica nanoparticles (MSNs) are inorganic nanoparticles composed of silica with 
uniform mesopores of diameter between 2 – 50 nm as per IUPAC.26 The first MSNs were 
discovered by Mobil researchers in 1992 which was named as Mobil Crystalline Materials (MCM-
41)
27
 for catalysis. MSN possess unique characteristics of high surface area, adjustable pore size 
and particle size, facile surface functionalization which lead to its application in adsorption, ion 
exchange, advanced catalysts, sensors and various other fields.
28-36
 Realising the potential of such 
inorganic silica nanoparticles, variety of MSN structures such as SBA-15
37
, MSU-1
38
, KIT-6
39
, 
FSM-16
40
, FDU family
41
 and many more are synthesized till date.   
 
Among the several properties of MSNs, uniform and tuneable pore size and ease of surface 
functionalization are the most important criteria which have enticed researchers for its diverse 
applications. More specifically, these properties play vital role in the field of pharmaceutical drug 
delivery and peptide/ protein encapsulation to enhance the properties of encapsulated drugs and 
peptides/ proteins. Maria Vallet-Regi et al. was first to report the application of MSN in drug 
delivery using Ibuprofen as the drug molecule.
25
  
 
2.2.1     Methods for pore size control  
 
The pore size is one of the most important features of MSNs for its application in catalysis by 
entrapping the metal particle in the pore channels or in drug delivery by encapsulating drug 
molecules in the pore channels. In catalysis, the entrapment of metal particle in smaller pores leads 
to smaller metal particle size resulting in larger surface area and high reactivity favouring faster 
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reactions. Similarly, in drug delivery the encapsulation of drug molecules in pore channels would 
lead to reduction in drug molecules at nanoscale leading to higher surface area and also changing its 
crystallinity to non-crystalline state. These effect leads to enhanced drug release. This advantage of 
pore channel size to enhance drug release has been widely studied using MCM-41, MCM-48 and 
SBA-15 materials. 
 
  Based on the Ostwald-Freundlich equation, we observed that, solubility of hydrophobic drugs 
increases dramatically when the particle size is below 10 nm. The commercial techniques to 
decrease drug particle size such as micronization, homogenizer, nanomilling, spray drying etc. face 
the limitation in which they are unable to reduce drug particle size below 100 nm and as these 
techniques involve mechanical stress it may lead to drug degradation.
12
 Hence, it is important to 
find a process by which we can reduce the drug particle size below 100 nm and more preferably 
below 10 nm.  
 
The existing techniques to control pore size thus can be broadly classified into three classes:  
a) Increasing the pore size by varying synthesis conditions,  
b) Decreasing the pore size using grafting process and  
c) ALD or CVD process. 
 
a) Increasing the pore size by varying synthesis conditions 
 
The pore size of MCM-41 was controlled by adjusting the pH of the synthesis mixture from pH 
11.5 to 10.0 resulting in pore size variation from 3.8 nm to 5.3 nm. This pH variation during 
synthesis causes change in the electrostatic charge distribution which affects the interaction of 
micelle head group resulting in pore expansion. The MCM-41 obtained by this process has different 
morphology based on the pH of the synthesis mixture.
42
 This method lacks fine pore size control 
and requires newly synthesized material to achieve pore size control.  
 
Pore size control on SBA-15 was achieved by varying the temperature and time of 
hydrothermal treatment in the presence of hexane as the micelle expander. Initial pore size of SBA-
15 (9.4 nm) was increased in the range of 11.9 nm – 18.2 nm by varying the hydrothermal treatment 
temperature from 40C – 130C and duration of hydrothermal treatment from 1 day – 5 days.43 The 
material obtained by this process have ordered structure (Ordered structure for SBA-15 is defined as 
the arrangement of pore channels with well-defined size and uniform shape yielding array of non-
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intersecting hexagonal channels over micrometer length scale.) however, the pore size control 
achieved by varying the synthesis conditions lacks fine pore size control.    
 
Pore size control was achieved on titanium containing MCM-41 (Ti-MCM-41) using swelling 
agents such as dodecylamine, n-heptane and trimethylbenzene. Use of the swelling agents – 
dodecylamine, n-heptane and trimethylbenzene resulted in pore size of 4.51 nm, 4.83 nm and 3.05 
nm compared to parent Ti-MCM-41 with 2.86 nm.
44
 The swelling agent did increase the pore size 
however it affected their ordered structure especially, with the inclusion of dodecylamine, the 
ordered structure was completely destroyed. Thus the pore size control achieved by this method has 
the disadvantage of affecting the ordered structure. Most importantly, the pore size control is in a 
broad range. 
 
b) Decreasing the pore size using grafting process 
 
Pore size reduction was achieved using a post grafting method on MCM-41 wherein 
trimethylchlorosilane (TMCS) was used as silica precursor. This method imparts hydrophobicity to 
MCM-41 material by the addition of methyl groups and reducing the pore size from 2.95 nm to 2.30 
nm.
45
 However, this method cannot be used in repetitive manner to further decrease the pore size 
and pore size reduction is at a relatively larger value.  
 
Pore size control was performed using supercritical fluids (SCF such as CO2) wherein FSM-16 
was used as the MSN. This method involved synthesizing FSM-16 using surfactants with varying 
alkyl chain length (n= 8, 10, 12 and 16) and then exposing to silica precursor (TEOS) dissolved in 
SCF under the influence of temperature and pressure. The pore size was reduced in a range of 0.1 – 
0.9 nm as the alkyl chain length increased for these materials and repeatability of the process was 
not discussed.
46
 
 
Pore size of MCM-41 was varied by selecting surfactants with different alkyl chain lengths. 
CnTAB surfactants with varying alkyl chain length, n= 16 and 12 used in the synthesis of MCM-41 
which resulted in pore size of 2.5 and 1.8 nm respectively.
25
 This method lacks fine pore size 
control and the material synthesis requires surfactants with different chain lengths. 
 
c) ALD or CVD process 
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Atomic layer deposition (ALD) process was utilized for pore size reduction on MSN. ALD is 
based on sequential self-limiting surface reactions which involve reaction of two gas phase 
molecules A, B in sequential manner with the substrate in ABAB... sequence. The gas molecule (A) 
react with surface species such as silanol groups adding the desired atomic element and changing 
the surface species to a new surface group. In subsequent step, (B) gas molecules react with this 
new surface group and add second desired atomic element. This second reaction with (B) gas 
molecules changes the surface group back to the original surface species. The overall reaction of A 
and B gas molecules results in a deposition of thin films at atomic scale.
47
 
 
ALD process was used to achieve pore size reduction in SBA-15 using TiCl4 and water as the 
precursors resulting in titania coated SBA-15. The pore size was reduced from 6.7 nm to 3.2 nm 
after 18 ALD cycles. Pore size reduction after each cycle was not measured however, on an average 
basis after 18 ALD cycles, pore size reduction was found to be 0.18 nm/ cycle.
48
 The average pore 
size reduction was in quite small range which would be beneficial in reducing pore size at angstrom 
scale however, inability to achieve such pore size reduction after each cycle makes this process 
unattractive. Also, the material obtained after ALD cycle was different from parent SBA-15 
because of titania coating on its surface.   
 
In another such study pore size reduction was attained on SBA-15 using niobium ethoxide and 
water as the precursors resulting in niobia coated SBA-15. The pore size reduced from 6.49 nm to 
5.80 nm, 5.60 nm, 4.75 nm and 3.74 nm after 1, 10, 19 and 30 ALD cycles respectively.
49
 The pore 
size reduction obtained is 0.1 nm on an average after 30 ALD cycles. However, this method results 
in material with niobia coating and does not give a precisely controlled size reduction after each 
ALD cycle similar to the above study.  
 
In another approach, chemical vapour deposition (CVD) process using water and tetraethoxy 
orthosilicate (TEOS) as the silica precursor was used to tailor the pore size of MCM-41 with initial 
pore size of 3.0 nm. MCM-41 was exposed to TEOS and water vapours alternatively in cyclic 
manner for three cycles followed by calcination. This process resulted in ink-bottle like structure 
with pore entrance of 1.35 nm and inner pore diameter of 3.0 nm. The average pore size reduction 
achieved by this process is 0.55 nm/cycle lacking fine control on pore size reduction after each 
cycle.
50
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Pore size control was achieved on SBA-15 material using metallorganic chemical vapour 
deposition (MOCVD) process wherein the pore opening was decreased from 5.78 nm to 3.7 nm 
using carbon and copper coating while retaining its pore volume and surface area forming an ink-
bottle like structure similar to MCM-41 mentioned earlier.
51
   
 
Different silica precursors such as TEOS and TMOS were utilized for pore size reduction of 
MCM-41 using CVD process by varying the number of  CVD cycles, deposition temperature (130, 
300 and 400C) and deposition time (3 and 6 hrs). Variation in temperature, time and number of 
CVD cycles decreased pore size in the range of 0.2 – 0.5 nm, 0.1 – 0.5 nm and 0.0 – 0.5 nm 
respectively. Pore size reduction achieved by this process varied widely displaying its limitation to 
control the pore size at narrow scale.
52
 
 
Thus the above existing techniques to control pore size face the limitation of precisely 
controlling the pore size change at angstrom scale after each cycle which is important parameter as 
per the Ostwald-Freundlich equation to achieve solubility enhancement as seen earlier. 
   
2.2.2      Methods for Surface functionalization  
 
MSN surface functionalization plays important role as they can control the drug release and 
targetability in vivo. MSN particles can be functionalized to impart positively charged surface using 
functional active agents such as 3-aminopropyltriethoxysilane (APTES),
53,54
 polyethyleneimine 
(PEI),
55,56
 polylysine,
57,58
  etc. or to impart negatively charged surface using polyphoshonate,
59,60
  
carboxylic acid,
61,62
 etc. or to impart hydrophobicity using Trimethylchlorosilane (TMCS)
45,63
 
Diethoxydimethylsilane (DEDMS),
64
 polymethylhydrosiloxane,
65
 hexamethyldisilazane
66,67
 etc. 
Drug molecules are encapsulated in the pores of MSN by electrostatic binding or hydrogen bonding 
or covalent bonding based on the functional group attached on its surface. This binding force in turn 
controls the drug release profile from the MSN pores. Moreover, the surface functionalization also 
helps in specific targeting of the tissues in in vivo studies. Specifically, the positively charged drug 
encapsulated MSN are preferred to target negatively charged cancer cells leading to higher 
cytotoxicity and efficacy.
68
 With this advantages offered by MSNs, materials like MCM-41, MCM-
48 and SBA-15 are more widely studied to achieve functional group driven drug release and 
targeting.  
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MSN surface functionalization is performed broadly by two methods: a) co-condensation, and 
b) postsynthetic grafting. 
 
 
Fig. 2.2 Schematic illustration for the synthesis and selective functionalization of MSNs. 
(reproduced from ref. 23) 
 
a) Co-condensation: 
 
In this method organosilane and organoalkoxysilane are mixed together during the synthesis in 
the gel solution with the surfactant assembly still present inside the pores as shown in step B of 
fig.4. This method results in positioning the organic moiety on the outer surface as shown in step C 
of fig.4. The surfactant assembly could be then removed using appropriate organic solution and HCl 
as shown in step D of fig.4. The empty pores can be used as cargo for loading drug or other genetic 
material.  This method offers advantage of being simple, achieving high and uniform distribution of 
functionalization. However, complete surfactant extraction would be subjected to solvent of choice 
during extraction.
26,36
  
 
b) Post synthetic grafting: 
 
This method allows the modification of MSN surface after the removal of surfactant template 
by either solvent extraction or calcination process. Functionalization can be achieved on both 
interior pore wall surface as well as external surface of MSNs. This is widely used method for 
functionalization of MSNs using functional groups which are chemically prone to hydrolysis and 
elimination reactions. To achieve different functional group coverage on interior and external 
surface of MSN, modification reaction can be started prior to surfactant template removal to have 
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surface coverage on external wall surface. The surfactant template can then be removed and interior 
pore surface which possess silanols groups can be used for second functionalization reaction.
26,36
 
  
2.2.3     Drug loading techniques 
 
 Since MSNs have found its application as drug delivery carriers, various drug loading 
methods have been used till date. Below are listed few methods which are employed for 
encapsulating drugs in MSNs:  
 
a) Immersion method  
 
In this method, MSNs are added to known volume and concentration of drug solution under 
stirring for a certain time. The drug loaded MSNs are obtained by filtering the suspension or by 
centrifugation and the filtrate or supernatant obtained is analysed by UV spectrophotometer to 
determine the drug loading amount. A known quantity of MCM-41 was added to 10 ml of 
0.1M Ibuprofen-hexane solution and stirred for 4 hrs. Ibuprofen loaded MCM-41 was obtained 
by filtering the suspension and analysing the filtrate by UV spectrophotometer.
69
 Similar 
approach was followed for encapsulating various drugs such as Famotidine,
62
 Captopril,
70
 
Doxorubicin,
71-73
 Camptothecin,
53,60
 Paclitaxel,
60
 Ibuprofen,
74-76
 Telmisartan,
77
 Prednisolone,
78
 
protoporphyrin IX,
79
 Fenofibrate,
80
 Curcumin,
81
 Sulfadiazine,
82
 Celecoxib,
83
 etc.  
 
b) Rotavap  
 
In this method, MSNs are added to known volume of drug solution and shaken for certain time. 
After which the solvent is slowly evaporated from the suspension using rotavapor at a reduced 
pressure with the aid of temperature. Indomethacin solution was prepared in ethanol and 
MCM-41 was added to it. Ethanol was slowly evaporated from the suspension at reduced 
pressure using rotavapor to obtain indomethacin loaded MCM-41.
84
 Similar approach was 
followed for encapsulating drug such as  Atazanivir.
85
 
 
c) Fluidized bed method 
 
Fluidized bed drier was used to encapsulate Indomethacin in MCM-41 by spraying the 
suspension of MCM-41 – Indomethacin solution. Indomethacin solution was prepared by 
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dissolving it in Ethanol. The rate of spraying and heating temperature in the fluidized bed drier 
helps in the encapsulation of indomethacin in the pores of MCM-41.
84
 
 
d) Impregnation  
 
This method involves soaking MSNs with drug solution under continuous stirring until dried 
powder is obtained resulting in impregnation of drug in pores of MSNs. In one such study, 
Fenofibrate was dissolved in methylene chloride at concentration of 50 mg/ml and added drop 
wise to MCM-41. This moist mixture was continuously stirred with spatula until dried powder 
was obtained.
86
 Similar approach was followed for encapsulating various drugs such as 
Aceclofenac,
87
 Carvedilol,
88
 Ezetimibe,
89
 Indomethacin,
90
 Glibenclamide,
90
 
 
2.3        MSNs as drug carriers 
 
 The first study of MSN as drug carriers was conducted using MCM-41 and Ibuprofen as the 
drug candidate.
25
 MCM-41 materials were prepared by employing two different surfactants – 
dodecyltrimethylammonium bromide (C12TAB) and hexadecyltrimethylammonium bromide 
(C16TAB) resulting in pore size of 2.5 nm and 1.8 nm respectively. Ibuprofen encapsulation in 
MCM-41 materials was performed by immersion method followed by conducting in-vitro drug 
release study. Drug release appeared to increase with the increase in the pore size thus 
demonstrating the application of MCM-41 as drug carrier.
25
  
  
Effect of MSN surface functionalization on drug loading and drug release was studied by 
comparing SBA-15 and MCM-41 with and without amino functionalization in this study. SBA-15 
and MCM-41 (with and without amino functionalization) materials were compacted into disc and 
soaked in sodium alendronate solution for its encapsulation. It was found that; sodium alendronate 
was loaded almost three times higher in amino functionalized MSN (SBA-15 and MCM-41) 
material compared to bare MSN (SBA-15 and MCM-41) material. This preferential higher loading 
in amino functionalized MSN material is attributed to the higher affinity of sodium alendronate to 
the amino groups on MSN. Drug release studies showed slower release of sodium alendronate from 
amino functionalized MSN compared to bare MSN thus demonstrating the influence of MSN 
surface functionalization on drug loading and drug release.
91
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 Effect of amino functionalized MCM-41 on drug release was reported using Ibuprofen as 
model drug wherein it was observed that, the drug release was slower for amino functionalized 
MCM-41 compared to bare MCM-41 demonstrating the influence of surface functionalization.
92
 
 
 In another report effect of amino functionalization amount on ibuprofen release was studied. 
3-aminopropyltriethoxysilane (APTES) was added in different stoichiometric ratio of 1, 3 and 6 
corresponding to the silanol number in MCM-41. It was observed that, the ibuprofen loading 
increased with increasing APTES amount with ratio of 6 showing highest ibuprofen loading which 
was attributed to the specific affinity between carboxylic group of ibuprofen and amino groups of 
APTES grafted on MCM-41. However the drug release decreases with increasing APTES amount 
which was due to the adsorption of drug in secondary mesopores of MCM-41. Thus choosing an 
optimal ratio of APTES plays important role in both drug loading and drug release.
76
       
 
 Influence of drug loading method on drug release was studied by encapsulating 
Indomethacin using three different methods – immersion, fluidized bed and rotavap in MCM-41 
followed by its compression as tablets. Amongst the different loading methods, fluidized bed and 
rotavap showed better drug loading and drug release compared to pure drug. Compression of these 
Indomethacin loaded materials into tablet did not affect the drug release and demonstrates its 
potential to be used as tablet.
84
 
 
 In another study, a hydrophobic plant growth regulator, namely the indole-3-butyric acid 
(IBA) was used as model drug to study its effect on dissolution after encapsulating it in MCM-41 
by immersion method. The drug release of IBA was higher from IBA encapsulated in MCM-41 
compared to the physical mixture and pure IBA. Moreover, the aqueous drug solubility was almost 
twice compared to pure IBA clearly displaying the advantage of utilising MCM-41 as the drug 
carrier.
93
    
 
 Mesoporous silica scaffold was used to encapsulate curcumin to improve its dissolution and 
photo stability. The drug loading was performed during the synthesis of mesoporous silica scaffold 
unlike the other methods where in the drug loading is performed post synthesis. The drug release 
studies were conducted in aqueous sodium hydroxide solution (pH 7.70) which showed controlled 
release of curcumin further confirming the application of MSNs as effective drug carrier system.
94
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 The drug release rate and bioavailability of fenofibrate, a poorly water soluble drug was 
controlled by controlling the pore size of SBA-15 and MCM-41. SBA-15 materials (pore size of 7.3 
nm and 4.4 nm) and MCM-41 materials (pore size of 2.7 nm) were loaded with fenofibrate by 
impregnation method. It was observed that under sink condition, drug release from SBA-15 (7.3 
nm) was very fast while that from SBA-15 (4.4 nm) and MCM-41 (2.7 nm) was relatively slow. 
Similar observation was seen in animal experiments where in the drug loaded MCM-41 exhibited 
highest concentration max. and highest area under the curve indicating more sustained super 
saturation of drug in instestinal media. Thus drug release was controlled by controlling the pore size 
which led to enhanced dissolution and bioavailability of poorly aqueous soluble drugs.
86
   
    
 In a subsequent study, a model hydrophobic drug, Itraconazole was encapsulated in SBA-15 
materials with pore size ranging from 4.5 nm, 6.4 nm, 7.9 nm and 9.0 nm. Itraconazole was loaded 
in SBA-15 materials by immersion method and the drug loading achieved was approximately 10 %. 
Drug release studies showed slower release from SBA-15 with pore size of 4.5 nm while faster 
release from SBA-15 materials with pore size above 6.4 nm. The slower itraconazole release from 
SBA-15 with pore size of 4.5 nm is attributed to molecular diffusion barrier leading to inability of 
itraconazole molecule to diffuse through the pore channel. Comparatively faster release from larger 
pore size SBA-15 materials is due to the easy diffusion of itraconazole proposing the existence of 
an optimized pore size for itraconazole to enhance drug release.
95
   
 
 Similar results were observed when Ibuprofen was encapsulated in MCM-48 which has two 
independent intertwined networks of pore channels (pore size = 3.7 nm) and SBA-15 which has 
unidirectional pore channels (pore size = 8.8 nm). The pore structure did not show any influence on 
the drug release however its pore size affected the drug release from first-order kinetics for MCM-
48 to zero-order kinetics for SBA-15. Thus, the pore size control plays a crucial role in modulating 
drug release.
96
  
 
 MSN was reported as carrier system for delivering hydrophobic anticancer drug, 
Camptothecin (CPT) using MCM-41. CPT encapsulated MCM-41 was tested in three pancreatic 
cancer-cell lines (PANC-1, Capan-1, and AsPc-1), a colon cancer-cell line (SW480), and a stomach 
cancer-cell line (MKN45) which showed almost complete inhibition similar to that of CPT 
dissolved in dimethylsulfoxide (DMSO) at 100 nm dose.
53
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 Further study of MSN for tumor suppression in pancreatic cancer was demonstrated using 
CPT as anticancer drug. MSN were grafted with folic acid as ligands on its surface to have 
specificity towards tumor cells followed by encapsulation of CPT by immersion method. 
Biocompatibility and excretion of MSN was studied in regular mice and found that MSNs are 
almost completely excreted within a week and they retain their morphology as well. CPT 
encapsulated MSNs were injected intraperitoneally at the dose of 7.8 µM to nude mice’s with 
established xenografts of human pancreatic cancer cells, PANC-1 and MiaPaca-2. CPT 
encapsulated folate grafted MSNs (FMSN) showed superior anti-tumor effect compared to CPT 
encapsulated MSNs and pure CPT with tumor volume reduced almost completely by 24 days in 
both PANC-1 and MiaPaca-2 xenograft in nude mice. This study systematically demonstrated the 
influence of folate receptors to achieve higher targetability to treat tumor using MSNs.
97
    
 
 The drug encapsulated in the pore channels of MSNs can have burst release at times as the 
pore entrance of these pore channels are open (without any capping) to the biological system. 
Hence, MSNs are closed or capped with chemical moieties which would help to achieve very less 
drug release or zero drug release in initial period. Several chemical moieties such as 
pseudorotaxanes,
98,99
 iron oxide, cadmium sulphate, β-cyclodextrins, etc. have been used as end 
capping agents. The end capped MSNs can then be further conjugated with specific ligands to 
achieve cell-specific targeting.  
 
 Redox-responsive MSN system was synthesized and end-capped with collagen to prevent 
drug leakage. Collagen which is one of the extracellular components was immobilized on the MSN 
surface by disulphide bonds. Disulfide bonds are easily cleaved by glutathione which are expressed 
by the cells and thus cargo encapsulated within the MSN pores can be released within the cells. 
Further lactobionic acid (LA) was grafted on the collagen as the ligand to targeting moiety. 
Fluorescein isothiocyanate (FITC) was used as the model drug in this study. The redox-
responsiveness of the system for controlled release of cargo was studied by using dithiothreitol 
(DTT) as external stimulus. 6.5% and 80% of FITC was released from MSN with LA grafted on 
collagen within 2 hrs in the absence and presence of DTT respectively indicating redox 
responsiveness of the system to DTT. The endocytosis of MSN with LA grafted on collagen study 
showed two times higher efficiency by HepaG2 cells (receptor for LA) compared to endothelial 
cells (non-receptor for LA).
100
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2.4 Cytotoxicity of MSNs 
 
Mesoporous Silica Nanoparticle has been proposed as the promising drug delivery system 
which is aptly supported by several studies conducted in the last decade. However, there are a few 
concerns regarding its biocompatibility, toxicity in scientific and industrial community. MSNs 
which are comprised of silica as the main component is accepted as “Generally Recognized As 
Safe” (GRAS) by the FDA. Silica in the form of colloidal silicon dioxide (also known as Aerosil) is 
a very well-known glidant and is one of the main excipients in tablets and also reported to find its 
applications in cosmetics and as food additive.
101,102
 Aerosil is reported to have LD50 of 1.5 mg/kg 
for intravenous administration in rats while LD50 of 3.16 g/kg for oral administration in rats 
proposing its safety.
103
 However, as the structure of MSNs is different from colloidal silicon 
dioxide, its biocompatibility relies on various aspects such as MSNs porosity, particle size, shape, 
surface functionalization, structure and concentration.  
 
The influence of MSN particle size on toxicity was studied by comparing MSNs with sizes 
of 190, 420 and 1220 nm on breast cancer cell line – MDA-MB-468 cells. MSNs with size of 190 
and 420 nm showed significant cytotoxicity at concentrations above 25µg/mL while MSN with size 
of 1220 nm showed slight cytotoxicity as it has decreased endocytosis.
104
 In another study it was 
seen that MSNs with size of 25, 42, 93, 155 and 225 nm showed concentration and size dependent 
hemolytic activity wherein the smaller MSNs showed higher hemolysis compared to larger ones.
105
 
A similar study further confirmed that, the silica particles with smaller size possess higher 
cytotoxicity. Silica particles with size below 20 nm showed higher cytotoxicity compared to silica 
particles with size of 104 and 335 nm.
106
   
 
Influence of dosage on cytotoxicity was evaluated where MSNs with size of 270 nm were 
found to be less toxic than silica particles with size of 2.5 µm and the cytotoxicity increased with 
increasing dosages in human monocyte-derived dendritic cells.
107
 Similar dosage dependent 
cytotoxic effect of MSNs was observed in a study on COS-7 and MDA-MB-468 cells. No 
cytotoxicity was observed until concentration of 25 µg/mL. However, above this dose, MSNs 
showed cytotoxicity.
108
   
 
Prolonged circulation of any drug loaded particles without being detected by 
reticuloendothelial system (RES) in the body is desirable to achieve better response. Surface 
modification with polyethylene glycols (PEGs) on MSNs is one such strategy which not only 
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avoids the RES detection but also increases the dispersity of particles
109
. In another study, effect of 
surface modification was evaluated by comparing aminopropyl and mercaptopropyl functionalized 
MCM-41 with unfunctionalized MCM-41 and non-porous silica nanoparticles for cytotoxicity in 
human neuroblastoma (SK-N-SH) cells. It was found that the unfunctionalized MCM-41 showed 
least cytotoxicity whereas aminopropyl functionalized MCM-41 and non-porous silica 
nanoparticles displayed highest cytotoxicity.
110
  
 
The influence of porosity on cytotoxicity was studied by comparing MSNs with non-porous 
silica nanoparticles in J774A.1 cells. It was found that MSNs showed less cytotoxicity than non-
porous silica nanoparticles.
111
 A study was conducted to evaluate the influence of porosity, particle 
shape and surface functionalization on toxicity and hemolysis in RAW 264.7 cell line. It was found 
that the non-porous silica nanoparticles were less toxic compared to MSNs while the particle shape 
did not influence the cytotoxicity. When studied for the effect of porosity and surface 
functionalization, it was observed that, the positive surface functionalization lead to higher 
hemolysis compared to the unfunctionalized silica materials. Unfunctionalized non-porous silica 
materials were found to be more biocompatible compared to the non-functionalized MSNs as they 
displayed less hemolysis. The MSNs with lower aspect ratio displayed higher hemolysis compared 
to MSNs with higher aspect ratio.
112
 
 
Cytotoxicity of silica materials was evaluated by conducting in vitro and in vivo studies for 
MCM-41 and non-porous silica nanoparticles. In vitro studies demonstrated that, the MCM-41 
display low cytotoxicity than non-porous silica nanoparticles. However, in vivo studies showed 
MCM-41 to be more cytotoxic compared to non-porous silica nanoparticles.
113
 Thus toxicity of 
MSNs is material and cell line dependent making it difficult to deduce any correlation. 
 
The fate of MSNs after administration in rats was studied by using two MSNs – positively 
and negatively charged MSNs. Positively charged MSNs was found to have rapid uptake and 
elimination via liver while the negatively charged MSNs had higher uptake and retention in liver. 
The impact of surface charge can thus be a useful parameter in designing effective nanoparticles 
with high residence time in the body to impart higher response.
114
 As this study was performed 
using a dye as model drug to demonstrate the influence of surface charge, we propose to study the 
effect of surface charge and hydrophobicity on drug release and cytotoxicity using model drugs – 
curcumin and griseofulvin. 
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Research Methodology 
 
The main objective of this thesis is to conduct a comprehensive study for enhancing the aqueous 
solubility of hydrophobic drugs (such as anticancer drug - curcumin) using mesoporous silica 
nanoparticles and evaluating the influence of surface functionalization on solubility, drug release 
and cytotoxicity. 
 
The first part of this thesis focuses on developing a technique to adjust the pore size of mesoporous 
silica nanoparticles (MSNs) at angstrom scale of 2-4 and 4-6 Å using two different silica precursors 
– tetraethoxyorthosilicate and tetramethoxyorthosilicate respectively. The series of MSNs materials 
obtained using the above process were thoroughly characterised and further a hydrophobic 
anticancer drug was encapsulated in them to study the influence of pore size on solubility.  
 
The second part of the thesis investigates the application of mesoporous silica nanoparticles as drug 
carrier system by encapsulating hydrophobic anticancer drug. The influence of mesoporous silica 
nanoparticles on enhancing the solubility, drug release and cytotoxicity was evaluated in 
comparison to pure drug.  
 
The third part focuses on the influence of surface functionalized mesoporous silica nanoparticles on 
cytotoxicity by encapsulating hydrophobic anticancer drug. Effect of surface charge and 
hydrophobicity on cytotoxicity was studied by conducting cell viability studies, cell cycle analysis, 
cell apoptosis study and reactive oxygen species generation studies. This part elucidates the role of 
surface functionalization in designing a effective drug carrier system. 
 
The fourth part of the thesis focuses on the influence of surface functionalized mesoporous silica 
nanoparticles on solubility and drug release by encapsulating hydrophobic anticancer drug. 
Interaction between the drug molecules and surface functionalized species was studied to evaluate 
its role in modulating the solubility and drug release which would help in selecting appropriate drug 
carrier system. 
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Chapter 4  
Stepwise Pore Size Reduction of Ordered Nanoporous Silica 
Materials at Angstrom Precision 
 
 
 
 
 
 
 
A facile vacuum-assisted vapor deposition process has been developed to control the pore size of 
ordered mesoporous silica materials in a stepwise manner with angstrom precision, providing an 
unprecedented paradigm for screening a designer hydrophobic drug nanocarrier with optimized 
pore diameter to maximize drug solubility. 
 
Chapter 4 is included as it appears in Journal of the American Chemical Society, 2013,135, 8444-
8447. 
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Chapter 5  
Mesoporous Silica Nanoparticles Enhance the Cytotoxicity 
of Curcumin 
 
 
 
 
Curcumin encapsulated in mesoporous silica nanoparticles showed improved solubility, in 
vitro release profile and significantly enhanced cell cytotoxicity compared to the pure drug. 
 
Chapter 5 is included as it appears in RSC Advances, 2014, 4(2), 709-712. 
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Chapter 6  
Effect of Surface Functionality of Silica Nanoparticles on 
Cellular Uptake and Cytotoxicity 
 
 
 
 
 
 
MCM-41 type mesoporous silica nanoparticles (MSNs) with different surface functional groups 
were synthesized as nanocarriers for curcumin (CUR). The effect of surface functionality 
(surface charge and hydrophobicity) on the delivery efficiency and anticancer activity in a 
human squamous cell carcinoma cell line (SCC25) was systematically studied. It was found that 
MSNs with hydrophobic surface did not enhanced curcumin’s cytotoxicity. Curcumin’s 
cytotoxicity was enhanced using MSNs with different surface charge and was comparable. 
 
Chapter 6 is published in Molecular Pharmaceutics, 2014, (DOI: 10.1021/mp500385n) 
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ABSTRACT  
Mesoporous silica nanoparticles (MCM-41) with different surface chemistry were used as carrier 
system to study its influence on drug delivery and anticancer activity of curcumin (CUR). CUR 
was encapsulated in pristine MCM-41 (hydrophilic and negatively charged), amino 
functionalized MCM-41 (MCM-41-NH2 which is hydrophilic and positively charged) and 
methyl functionalized MCM-41 (MCM-41-CH3 which is hydrophobic and negatively charged) 
and evaluated for in vitro release and cell cytotoxicity in human squamous cell carcinoma cell 
line (SCC25). Various techniques were employed to evaluate the performance of these materials 
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on cellular uptake and anticancer activity in SCC25 cell line. Both positively and negatively 
charged surface demonstrated enhanced drug release and anticancer activity compared to pure 
curcumin. Positively charged nanoparticles showed higher cell uptake compared to negatively 
charged nanoparticles owing to its electrostatic interaction with cells. However, hydrophobic 
surface modified nanoparticles (MCM-41-CH3) showed no improvement in drug release and 
anticancer activity due to its poor wetting effect. Cell cycle analysis and cell apoptosis studies 
revealed different pathway mechanisms followed by the positively and negatively charged 
nanoparticles but exhibiting similar anticancer activity in SCC25 cells. 
1.  INTRODUCTION 
Cancer is a complex, multifactorial disease that results from strong interplay between genetic, 
environmental, viral, social and behavioral factors where majority of the therapeutic modality 
become increasingly ineffective. A recent report projects 1% annual increase in cancer 
occurrence and mortality, leading to about 26.8 and 17.1 million new cancer cases and cancer 
related deaths respectively every year by 2030.
1
 Hence, development of more effective therapy 
to combat cancers is urgently needed. The challenges in cancer chemotherapy are associated with 
adverse toxicity leading to damage of normal cells and tissues; and resistance mediated 
inactivation of drugs.
2
 A growing urge to develop multi-targeted anti-cancer drug molecules 
from natural products derived phytochemicals have become a focus of modern research due to 
their minimal side effects and potent chemo-preventive properties.  
Curcumin, a natural phytochemical was reported to inhibit the proliferation of multiple cancer 
cells including breast, colon, pancreas, gastric, liver, blood, lung, prostate, bladder, cervix, ovary, 
head and neck, brain, multiple myeloma, leukemia, and lymphoma by arresting them in various 
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phases of the cell cycle and by inducing apoptosis.
3,4
 The anti-cancer properties of curcumin are 
mediated through regulation of various transcription factors, growth factors, inflammatory 
cytokines, protein kinases, and other enzymes. Curcumin induced therapeutic efficacy against 
cancers, inhibition of angiogenesis and metastasis in animal models are reported and its anti-
cancer potential has been studied in clinical trials.
5
 Curcumin being a potent anti-cancer 
molecule targets many signaling pathways however; its therapeutic efficacy is hindered by non-
specific delivery, suboptimal tissue distribution, and rapid metabolism culminating suboptimal 
bioavailability due to poor aqueous solubility.
6,7
  
Curcumin delivery systems such as surfactant complexes, liposomes, hydrogels, and polymeric 
nanoparticles have been developed to alleviate these issues with limited success due to their 
synthesis complexity and poor biological stability.
8-10
 Mesoporous silica nanoparticles (MSNs) 
with rigid inorganic frameworks have attracted increasing attention as drug delivery carriers
11,12
 
owing to their unique properties.
13
 Earlier, curcumin was either encapsulated in 
cetyltrimethylammonium bromide (CTAB) micelle followed by silica coating
14
 or encapsulated 
in modified silica particles as model drug to evaluate its pH dependent in vitro release 
performance
15,16
 or conjugated with solid silica to demonstrate its cytotoxic activity.
17
 However, 
the surfactant used in the study (CTAB) is reported to be toxic to the cells
18,19
 or ammonia which 
was used as the reagent can lead to curcumin instability as alkaline condition degrades 
curcumin
20
 or the release medium selected could degrade curcumin.
21
 In our previous studies we 
have demonstrated enhanced curcumin release and cell cytotoxicity by encapsulating it in 
MSNs.
22
 Surface charge and hydrophobicity of MSNs are important parameters which are 
reported to modulate the drug release and its activity.
23,24
 It is well reported that the positively 
charged particles demonstrate higher endocytosis in cancer cells due to electrostatic attraction as 
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these cells are negatively charged. There are few studies which report the hydrophobicity helps 
in controlling drug release.
25
 We would like to study the influence of surface functionalisation of 
MSNs on cellular response when encapsulated with curcumin. 
In this work, we report the influence of surface charge and hydrophobicity on curcumin’s release 
and cell cytotoxicity by encapsulating CUR in pristine MCM-41 (hydrophilic and negatively 
charged), amino functionalized MCM-41 (MCM-41-NH2 which is hydrophilic and positively 
charged) and methyl functionalized MCM-41 (MCM-41-CH3 which is hydrophobic and 
negatively charged). It is observed that, MCM-41-CUR displays higher drug release compared to 
MCM-41-NH2-CUR and MCM-41-CH3-CUR (Scheme 1). Moreover, the cellular uptake was 
found to be higher for MCM-41-NH2-CUR compared to MCM-41-CUR. Cell inhibitory studies 
demonstrated similar cytotoxic activity by MCM-41-CUR and MCM-41-NH2-CUR. Flow 
cytometry and cell apoptosis studies conducted to understand the mechanism followed by these 
nanoparticles suggests different mechanisms followed by them but still displaying similar 
anticancer activity which were comparable to the organic CUR-DMSO solution. 
2. MATERIALS AND METHODS 
2.1 Materials  
Cetyl trimethylammonium bromide (CTAB), tetraethoxy orthosilicate (TEOS), (3-Aminopropyl) 
triethoxysilane (APTES), chlorotrimethylsilane (TMCS), sodium lauryl sulphate (SLS) and 
Curcumin (CUR) were purchased from Sigma-Aldrich. Reagent grade sodium hydroxide 
(NaOH) was received from ChemSupply. Methanol AR and Toluene was purchased from RCI 
labscan and Merck respectively. Human squamous cell carcinoma SCC25 cell line was a kind 
gift of Prof. Nicholas Saunders from the Princess Alexandra Hospital, Brisbane. Dulbecco's 
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Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) media was purchased from 
Sigma. Fetal calf serum was purchased from Moregate biotech. Paraformaldehyde and antifade 
fluorescent mounting medium with 4’-6-diamidino-2-phenylindole (DAPI), Thiazolyl Blue 
Tetrazolium Bromide (MTT) cell viability dye, Propidium iodide (PI), Ribonuclease A were 
purchased from Sigma-Aldrich. Annexin V-FITC kit was from BD Biosciences. 
2.2. Characterization 
X-ray diffractograms (XRD) were recorded on a Rigaku Miniflex X-ray diffractometer with Fe-
filtered Co radiation (λ = 1.79 Å). Transmission electron microscopy (TEM) images were 
obtained with a JEOL 1010 operated at 100 kV. Nitrogen physisorption measurements were 
carried out at -196 °C by using a Micromeritics Tristar II 3020 system. MCM-41, MCM-41-NH2 
and MCM-41-CH3 sample were degassed at 100 C whereas MCM-41-CUR, MCM-41-NH2-
CUR and MCM-41-CH3-CUR samples were degassed at 50 C overnight on a vacuum line. The 
pore-size distribution was measured from the adsorption branch of the isotherm using BJH 
model. Fourier transform infrared (FTIR) spectra were recorded on ThermoNicolet Nexus 6700 
FTIR spectrometer equipped with Diamond ATR (attenuated total reflection) Crystal. For each 
spectrum, 128 scans and 4 cm
-1
 resolution was applied over the range of 400–4000cm-1. Raman 
scattering studies were carried out using a laser excitation wavelength of 780 nm using the 
Nicolet Almega Visible Raman spectrometer. For each spectrum, 32 scans and 4 cm
-1
 resolution 
was applied over the range of 400–4000cm-1. Zeta potential was measured on a Malvern 
Zetasizer Nano-ZS. The thermogravimetric (TGA) and Differential Scanning Calorimetry (DSC) 
measurements were performed by a Setaram TG92 instrument with a heating rate of 2 C/min in 
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air flow. Curcumin concentration was determined using UV-VIS spectrophometer (Shimadzu 
UV-2450). 
2.3. Synthesis of MCM-41  
MCM-41 synthesis was performed according to the previously reported method by Yang et al. 
with slight modification.
26
 Briefly, 1.0 g of CTAB was dissolved in 480 g of deionized water at 
room temperature and kept under stirring until clear solution. 3.5 mL of NaOH (2 M) was added 
to this solution and temperature increased to 80 °C. Once the solution reaches 80 °C, 6.7 mL of 
TEOS was added into the mixture as the silica source under continuous stirring for an additional 
2 h. The resultant product was obtained by filtration and dried at room temperature. The as-
synthesized MCM-41 was divided into three parts. One part was calcined at 550 °C for 5 h to 
remove the surfactant template and denoted as MCM-41. Second part was calcined in a process 
similar to the first one and subjected to methyl modification process and denoted as MCM-41-
CH3. The remaining as-synthesized MCM-41 was utilized for amino modification and the 
surfactant template was removed by solvent extraction process. This material was denoted as 
MCM-41-NH2. Two different method of surfactant removal were employed to obtain materials 
with similar pore size after the functionalization process. 
2.4. Synthesis of methyl modified MCM-41  
Methyl modification on MCM-41 was performed according to published report.
27
 0.4 g of 
calcined MCM-41 was added to 20 mL of TMCS solution in toluene with a concentration of 5 
wt% under stirring at 70 °C. This suspension was stirred for additional 24 h at 70 °C. The methyl 
Chapter 6 
Effect of Surface Functionality of Silica Nanoparticles on Cellular Uptake and Cytotoxicity 
 
82 
 
functionalized MCM-41 was then centrifuged and washed with toluene and ethanol. The material 
was then dried at 50 °C overnight before subjected to further studies. 
2.5. Synthesis of amino modified MCM-41  
Amino modification was performed according to published report with slight changes.
28
 0.4 g of 
as-synthesized MCM-41 was added to 25 mL of methanol under stirring at RT followed by the 
addition of 1.5 mL of APTES. The suspension was stirred overnight at RT. The amino 
functionalized MCM-41 with surfactant template still present in it was then retrieved by 
centrifugation and washed with methanol twice. The material was then dried at 50 °C overnight 
before subjected to solvent extraction process for surfactant template removal. 
 Surfactant template was removed by a reported method by Lu et. al.
29
 with some modification. 
0.3 g of material was added to 32 mL of methanol under stirring and the temperature was 
increased to 60 °C. To this suspension, 2.0 mL of conc. HCl was added and kept under 
continuous stirring for 36 h. Later the suspension was centrifuged and washed with methanol 
twice to ensure complete surfactant removal. The final product was dried at 50 °C overnight to 
be used for further studies.   
2.6. Curcumin loading  
Curcumin loading was performed using rotary evaporation technique.
22
 160  mg of MCM-41 was 
placed in rotary evaporation flask and 40 mg of Curcumin was added to it followed by the 
addition of 10 mL of methanol. This mixture was sonicated for 2 mins and the solvent was 
slowly evaporated using rotary evaporator at 50 C with circulating water temperature 
maintained at 5 C to obtain curcumin loaded MCM-41. Evaporation process was continued till 
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all the solvent is removed and dried powder can be observed in the flask. Dried Curcumin loaded 
MCM-41 sample (MCM-41-CUR) was collected from the flask and used for further studies. 
Similar procedure was followed for MCM-41-NH2 and MCM-41-CH3 materials. Dried curcumin 
loaded MCM-41-NH2 and MCM-41-CH3 materials are denoted as MCM-41-NH2-CUR and 
MCM-41-CH3-CUR respectively.    
2.7. In vitro release studies  
The in vitro release of curcumin from MCM-41-CUR, MCM-41-NH2-CUR and MCM-41-CH3-
CUR was evaluated using dialysis bag technique.
30,31
 MCM-41-CUR equivalent to 1 mg of CUR 
was weighed and suspended in 1 mL of 0.5 % SLS. This suspension was then placed in dialysis 
bag with 10 kDa molecular weight cutoff and was  immersed into 9 mL of 0.5 % SLS at 37 °C 
with continuous stirring. At predetermined time intervals, 1 mL of the samples were withdrawn 
and immediately replaced with an equal volume of dissolution medium to maintain the sink 
condition. These samples were then properly diluted and analyzed for curcumin content at 432 
nm using UV-VIS spectrophotometer. Similar process was performed for MCM-41-NH2-CUR 
and MCM-41-CH3-CUR materials to evaluate their drug release and compared with pure CUR (1 
mg).
2.8. In vitro cytotoxicity assay 
The human squamous cell carcinoma SCC25 cell line was propagated in a monolayer to sub-
confluency at 37°C in 75 cm
2
 flasks containing 10 mL of DMEM:F12 media, supplemented with 
heat inactivated 10% fetal calf serum (FCS), 1% penicillin, 1% glutamine and 1% streptomycin 
and hydrocortisone (0.4µg/mL) in a fully-humidified incubator containing 5% CO2 and 95% air. 
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The sensitivity of SCC25 cells to the curcumin nano-formulation was determined by the MTT 
colorimetric assay. Cells (1×10
4
 per well) were seeded in a flat-bottomed 96-well plate and 
incubated at 37 °C and in 5% CO2. Cells were exposed to blank MSNs or encapsulated with 
curcumin at the concentrations of 15, 30, and 45 μg/mL in a dose and time dependent manner for 
24, 48 and 72 h. Cells were then treated with MTT reagent (10 μL/ well volume from 5 mg/ mL 
solution in PBS) for 4 h at 37 °C. Then DMSO (100 μL) was added to each well to dissolve the 
formazan crystals. The optical density (OD) was recorded at 570 nm in a microplate reader and 
percentage of residual cell viability was determined. All experiments were performed in 
triplicate. 
2.9. Measuring curcumin delivery in vitro by confocal microscopy 
The autofluorescence of curcumin (Ex = 480 nm – 530 nm) was used to measure the curcumin 
uptake by SCC25 cells by confocal microscopy. Briefly, SCC25 cells were seeded onto glass 
coverslips (Nalge NUNC International, Rochester, New York) at a density of 2 × 10
5
 cells per 
well and cultured overnight. The next day, the culturing media was removed, and replaced with 
serum free medium containing CUR in DMSO, CUR in DMEM, MCM-41, MCM-41-NH2, 
MCM-41-CUR or MCM-41-NH2-CUR at a final curcumin concentration of 15 μg/ mL. After 
incubation at 37 °C for 4 hours, the media were removed from the cells, washed with PBS, fixed 
with 4% w/w paraformaldehyde in PBS and imaged at 630X magnification using a Zeiss LSM 
710 META confocal microscope (Carl Zeiss, Thornwood, New York). 
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2.10. Silica ICP-OES study 
This study was carried out to measure the silica nanoparticles endocytosis performance in human 
squamous cell carcinoma SCC25 cells (5×10
4
 cells per well of 6 wells plate) for MCM-41-CUR 
and MCM-41-NH2-CUR. The SCC25 cells were treated similar condition as mentioned in MTT 
assay and cells from each treatment were washed twice with cold phosphate-buffered saline 
(PBS, pH 7.4). The cells from both groups were collected separately after 4 and 24 h following 
trypsinization and then washed twice with PBS and centrifuged at 5000 rpm for 10 min. Cell 
lysate were prepared in 200µL ice-cold (4 °C) 1X cell lysis buffer (20 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 
mM beta-glycerophosphate, 1 mM Na3VO4, 1 µg/mL leupeptin) followed by sonication. Cell 
lysates were then centrifuged for 10 minutes at 14,000 rpm at 4 °C and pellet fractions were 
collected and dissolved in 200µL of 1M NaOH solution. The collected samples (n=3) were then 
diluted in PBS and sent to the Agricultural Biotechnology Center at University of Queensland for 
ICP analysis of Si and expressed in mg/L unit. 
2.11. Cell Cycle analysis 
For the analysis of cell cycle, SCC25 cells treated with CUR in DMSO, CUR in DMEM,  MCM-
41-CUR, MCM-41-NH2-CUR (15 µg/mL) were fixed in chilled 70% ethanol and were labeled 
with PI (50 μg/mL) and RNase (100 μg/mL) for 30 min before the analysis by flow cytometry 
(BD LSR II Analyser) with Multi-cycle system software package. For each measurement, at least 
10,000 cells were counted. Cell cycle analysis was performed for 24 h to evaluate the activity 
based on different cell cycle phase. 
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2.12. Annexin V / PI staining 
SCC25 cells were treated with CUR in DMSO, CUR in DMEM, MCM-41-CUR, MCM-41-NH2-
CUR (15 µg/mL) for 24 h and were harvested and washed with PBS after the treatment. The 
cells were first incubated with 100 μL of binding buffer and stained with 5 μL Annexin V-FITC 
and 5 μL of propidium iodide (PI) from kit according to vendor's instruction (BD Bioscience, 
Australia) at room temperature for 15 min in the dark. The cells were then analysed by flow 
cytometry (BD LSR II Analyser) and 10,000 cells were counted. Data were analysed and plotted 
for Annexin V-FITC and PI in a two-way dot plot. Live, early apoptotic and late 
apoptotic/necrotic cells are designed as annexin-/ PI-, annexin+/ PI-, and annexin+/ PI+, 
respectively. 
2.13. ROS assay 
For cellular ROS measurement, SCC25 cells was seeded on 96 well/plates overnight and next 
day incubated with the 10-μM carboxy-2’,7’-dichloro-dihydro-fluorescein diacetate (DCFH-DA) 
probe at 37 °C for 30 min. At the end of this period, medium was removed and replaced with 
fresh serum free medium and cells were treated with CUR in DMSO, MCM-41-CUR and MCM-
41-NH2-CUR at concentration of 15 µg/mL. After initial incubation at CO2 incubator at 37 °C, 
fluorescence was measured on a microplate reader (Molecular Devices Spectra MAX) for 0.2-6 h 
for each time period at 485 nm (excitation) and 527 nm (emission) wavelengths. All assays were 
performed in triplicate.  
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3. RESULTS 
3.1. Material characterization 
The X-ray diffraction (XRD) patterns of MCM-41 (Fig. 1A) show three well resolved diffraction 
peaks at 2θ of 2.44, 4.27 and 4.93° with a reciprocal d-spacing ratio close to 1: √3: 2, which can 
be indexed as 100, 110 and 200 reflections of an ordered two dimensional (2D) hexagonal 
mesostructure with a pore symmetry of p6mm. The positions of three diffraction peaks for 
MCM-41-CH3 are similar to that of MCM-41 demonstrating retention of ordered structure after 
surface functionalization. However, we can observe a shift for the three diffraction peaks in 
MCM-41-NH2 compared to that of MCM-41 and MCM-41-CH3. The diffraction peak positions 
of MCM-41 materials after curcumin encapsulation was unaltered to that of MCM-41 materials 
before curcumin encapsulation demonstrating the retention of the ordered structure.  
To confirm the crystalline nature of curcumin encapsulated in MCM-41 materials, wide angle 
XRD (WXRD) study was performed. WXRD patterns (Fig. 1B) were obtained for MCM-41 
materials with and without curcumin loading along with the physical mixtures of curcumin and 
respective MCM-41 materials. Pure curcumin is a crystalline compound showing sharp 
diffractions in the 2θ range of 10-40. The amorphous nature of MCM-41, MCM-41-NH2 and 
MCM-41-CH3 materials is evidenced from the broad peak in the range of 2θ 20-30.
32,33
 The 
physical mixture of three MCM-41 materials and curcumin (MCM-41-CUR PM, MCM-41-NH2-
CUR PM and MCM-41-CH3-CUR PM) show diffraction peaks corresponding to pure curcumin. 
However, for curcumin encapsulated MCM-41 materials obtained using rotary evaporation 
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technique (MCM-41-CUR, MCM-41-NH2-CUR and MCM-41-CH3-CUR), no obvious 
diffraction peaks originating from CUR can be observed.  
Typical TEM images of MCM-41, MCM-41-NH2 and MCM-41-CH3 are shown in Fig. 2. 
Because three materials were prepared from the same mother solution, they show similar 
morphologies as nanoparticles with ~ 100 nm in size. For each particle shown in Figs. 2a-c, 
parallel channel-like or hexagonally arrayed porous structures can be seen, in accordance with a 
hexagonal mesostructure. The TEM results also suggest that surface functionalization of MCM-
41 in our experiments did not affect the hexagonal structure, consistent with the XRD 
characterisations.  
The nitrogen adsorption/ desorption isotherm of MCM-41, MCM-41-NH2 and MCM-41-CH3 
correspond to a typical type IV isotherm and show a steep capillary condensation step at a 
relative pressure (P/P0) range of 0.2-0.4 (Fig. 3A), characteristic of a mesoporous material. From 
the pore size distribution curves (Fig. 3B), it is shown that MCM-41 material has a pore size of 
2.17 nm. MCM-41-NH2 has a pore size of 2.10 nm, suggesting that the modified amino grafting 
method helps in achieving pore size similar to MCM-41. MCM-41-CH3 exhibits a pore size 
centered at 1.80 nm, suggesting slight decrease in the pore size. After encapsulating curcumin, 
the pore size of MCM-41-CUR, MCM-41-NH2-CUR and MCM-41-CH3-CUR have been 
decreased to 2.10, 1.91, and 1.73 nm, respectively. The drug encapsulation also results in 
decrease in surface area and pore volume. For example, the surface area and surface volume for 
MCM-41-CUR decreases to 450 m
2
/g and 0.44 cm
3
/g compared to MCM-41 from 995 m
2
/g and 
0.79 cm
3
/g respectively. Similar trend was observed for MCM-41-NH2-CUR and MCM-41-CH3-
CUR materials as well. All the textural parameters are summarized in Table 1 for comparison.  
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The surface modification of MCM-41 materials was checked by measuring zeta potential (Z.P.) 
As shown from Table 1, MCM-41 shows a Z.P. of -36.4 ± 1.42 mV, while MCM-41-NH2 and 
MCM-41-CH3 display Z.P. of 36.3 ± 2.52 and -18.2 ± 1.40 mV, respectively, confirming the 
successful surface modification of MCM-41 materials. The surface modification is also 
evidenced by dispersing the materials in ether – water composition as shown in Fig. 3C. Both 
MCM-41 and MCM-41-NH2 materials were totally dispersed in aqueous phase with a hazy 
appearance while MCM-41-CH3 material was completely dispersed in organic phase  
3.2. Adsorption of curcumin 
Modification of MCM-41 materials with amino and methyl groups as well as the encapsulation 
of curcumin in MCM-41 materials was further confirmed by FTIR analysis as shown in Fig. 4. 
Pristine MCM-41 material exhibits two peaks at 810 and 1060 cm
-1
 (Fig. 4C) and two bands with 
low intensity at 3745 cm
-1
 and 1630 cm
-1
  (Figs. 4A and 4B). The silanol peak disappeared when 
amino and methyl modifications are performed on MCM-41. The amino modification resulted in 
appearance of peaks at 2929, 1631 and 1518 cm
-1
 whereas the methyl modification results in the 
peak at 2964 cm
-1
 and band of peaks at 1255, 848 and 758 cm
-1
. Pure curcumin displays a sharp 
peak at 3507 cm
-1
 and a broad peak at 3293 cm
-1
. These peaks are not observed in MCM-41-
CUR. Instead a new broad peak centered at 3428 cm
-1
 (Fig.4A) can be seen in MCM-41-CUR. 
Additionally, other typical peaks displayed by pure curcumin can be observed in MCM-41-CUR 
(Figs. 4B and 4C). Similar results were observed for MCM-41-NH2 and MCM-41-CH3 samples. 
The peak at 1506 cm
−1
 seen in the case of curcumin undergoes a shift to 1513 cm
−1
 in the case of 
MCM-41-CUR, MCM-41-NH2-CUR and MCM-41-CH3-CUR. The peaks due to δ(CCH) of the 
phenol and skeletal δ(CCH) at 1145 cm−1 due to in-plane bending vibrations and the peak at  
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1023 cm
−1
 due to the in-plane bending vibrations of aromatic keto group δ(CCH) and out of 
plane vibrations of CH3, i.e., δ(CH3) of curcumin are masked by the asymmetric Si-O-Si 
stretching vibrations of MCM-41 materials. The peak at 1272 cm
−1
 due to aromatic keto in-plane 
vibrations δ(CCH), δ(CCC) and keto-enol δ(COH) are found to have merged with Si-O-Si 
stretching vibrations of MCM-41 materials. In short all the major peaks of curcumin shown in 
fig. 4C are hidden by the IR vibrations of MCM-41 materials without curcumin encapsulation in 
the similar regions. Although we can observe very weak signals in the range of 1400-1500 cm
−1
 
in the curcumin encapsulated MCM-41 materials which coincide with the peaks of pure CUR, it 
does not explains the curcumin encapsulation in MCM-41 materials conclusively. Hence, we did 
the Raman spectra for curcumin encapsulated MCM-41 materials.  
Raman spectral studies revealed that the absence of (C=O) peaks in the region of 1650-1800 
cm
−1
 for pure curcumin indicating its existence in enol form rather than its diketone form (Fig. 
5).
34
 A peak shift was observed from 1633 cm
−1
 for pure curcumin to 1640 cm
−1
 in MCM-41-
CUR. Similar results were observed for MCM-41-NH2-CUR and MCM-41-CH3-CUR  
TGA analysis was used to evaluate the curcumin encapsulation in different samples under study 
(Fig. 6A). Curcumin concentration loaded in MCM-41-CUR, MCM-41-NH2-CUR and MCM-
41-CH3-CUR materials by rotary evaporation technique was found to be 20.02 %, 16.95 % and 
19.98% respectively indicating high efficiency of rotary evaporation process in accordance with 
previous reports.
22,35
 For comparison, physical mixtures of curcumin and MCM-41, MCM-41-
NH2 and MCM-41-CH3 materials were prepared.  MCM-41-CUR PM, MCM-41-NH2-CUR PM 
and MCM-41-CH3-CUR PM samples showed weight loss of 22.67%, 18.95% and 20.90% 
respectively (Fig. 7A). The hydrophobic modification inhibits the aqueous wetting of MCM-41-
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CH3 by methyl groups present on the material which is evident by the % wt. loss at 100C as 
seen from Fig. 6A and 7A.  The moisture loss for MCM-41 and MCM-41-NH2 is 3 and 9 % 
whereas 1 % for MCM-41-CH3 material thus demonstrating the effect of hydrophobicity on 
moisture uptake. 
Differential Scanning Calorimetry (DSC) analysis was performed to determine the crystallinity 
of curcumin in MCM-41-CUR, MCM-41-NH2-CUR and MCM-41-CH3-CUR samples (Fig. 6B). 
Pure curcumin (CUR) displays a sharp melting point peak at 176C. A weak signal can be 
observed for MCM-41-CUR PM, MCM-41-NH2-CUR PM and MCM-41-CH3-CUR PM samples 
(Fig. 7B). However, this peak cannot be observed in MCM-41-CUR, MCM-41-NH2-CUR and 
MCM-41-CH3-CUR samples (Fig. 6B)  
3.3. In vitro release  
To compare the effect of surface charge and hydrophobicity in curcumin encapsulated MCM-41 
materials, curcumin release was studied in 0.5% SLS (under sink conditions) as the dissolution 
medium. After 1 h, the release of curcumin from MCM-41-CUR, MCM-41-NH2-CUR and 
MCM-41-CH3-CUR was found to be 0.67%, 0.38% and 0.76% respectively compared to 0.97% 
from pure Curcumin (Fig. 8). The drug release profile increased slowly for MCM-41-CUR 
(28.0%), MCM-41-NH2-CUR (22.63%) and MCM-41-CH3-CUR (19.35%) after 72 h compared 
to pure curcumin (11.19%). MCM-41-CUR showed higher curcumin release compared to MCM-
41-NH2-CUR, MCM-41-CH3-CUR and pure curcumin at all time points.  
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3.4. In vitro cytotoxicity of curcumin 
To determine the efficacy of curcumin encapsulated MSNs on cancer cell viability, MTT assay 
was conducted on human squamous cell carcinoma SCC25 cell line. SCC25 cells were treated 
for 24, 48 and 72 h with 0, 15, 30 and 45 μg/mL concentrations of free curcumin (curcumin in 
DMEM and curcumin in DMSO) and equivalent doses of MCM-41-CUR and MCM-41-NH2-
CUR and MCM-41-CH3-CUR dispersed in DMEM. Respective blank MSNs without curcumin 
loading were also evaluated as control groups (Fig. 9).  
As shown in Fig. 9, CUR-DMEM shows dose and time dependent toxicity until 48 h with no 
further improvement on exposing them for longer duration (72 h). The maximum cell viability 
demonstrated by CUR-DMEM was 50 % at 48 h at the dose of 45 ppm. On the contrary, CUR-
DMSO showed a strong inhibitory effect on cell viability within 24 h which was further 
increased at 48 h and 72 h demonstrating the anticancer potency of curcumin. MCM-41-CUR 
showed a dose dependent decrease in cell viability within 24 h which was maintained up to 72 h. 
Similarly, MCM-41-NH2-CUR induced a dose dependent inhibition on SCC25 cell viability 
within 24 h which were further potentiated at 48 h and 72 h. On the other hand, MCM-41-CH3-
CUR induced minimal cytotoxicity and hence, we have omitted MCM-41-CH3-CUR group from 
all further biological studies. Interestingly, the cell inhibitory potential of MCM-41-CUR (at 72 
h) and MCM-41-NH2-CUR (at 48 h and 72 h) are very well comparable to that of CUR-DMSO 
which is far more potent than CUR-DMEM response. These observations show the advantages 
of nanoparticles mediated delivery of curcumin in aqueous based formulation to exert desirable 
therapeutic effect and to avoid organic solvent toxicity. None of the blank MCM-41 
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nanoparticles showed reduction in cell viability up to 72 h indicating their biocompatibility and 
bioinertness.  
3.5. Cellular uptake studies 
Cell uptake efficiency for curcumin by CUR-DMEM, CUR-DMSO, MCM-41-CUR and MCM-
41-NH2-CUR in SCC25 cells was studied by confocal microscopy. The curcumin uptake by 
SCC25 cells from all four formulations – CUR-DMEM, CUR-DMSO, MCM-41-CUR or MCM-
41-NH2-CUR, showed a marked difference in curcumin levels compared with untreated control 
group (Fig. 10). Cells incubated with CUR-DMEM for 4 hours had very nominal and 
undetectable curcumin level. MCM-41-NH2-CUR showed highest accumulation in cell cytosol 
whereas CUR-DMSO and MCM-41-CUR both showed relatively reduced level of curcumin 
accumulation in cytosol. CUR-DMSO had organic solvent, DMSO which is able to dissolve 
curcumin completely and thus is well accumulated inside SCC25 cells. MCM-41-NH2-CUR 
showed superior curcumin uptake compared to MCM-41-CUR.  
To further support the cell uptake studies, silica content was measured by silica inductively 
coupled plasma atomic emission spectroscopy (ICP-OES) study. MCM-41-CUR and MCM-41-
NH2-CUR were incubated with SCC25 cells for 4 and 24 h and measured for their silica content. 
Positively charged MCM-41-NH2-CUR showed higher Si content at 4 h compared to the 
negatively charged MCM-41-CUR (Fig. 11). However, with further incubation (24 h) the Si 
content reduced for MCM-41-NH2-CUR while it was unchanged for MCM-41-CUR 
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3.6. Cell cycle and apoptosis studies 
To determine the impact of four curcumin formulations – CUR-DMEM, CUR-DMSO, MCM-
41-CUR and MCM-41-NH2-CUR on the cell cycle, SCC25 cells were treated with 15 μg/mL 
equivalent curcumin concentrations for 24 h. PI stained cells were analysed by flow cytometry 
analysis to determine alterations in distribution of cells in different phases of cell cycle (Fig. 12). 
Results from flow cytometry analysis in SCC25 cells showed that treatment with CUR-DMEM, 
blank MCM-41 and blank MCM-41-NH2 did not alter the cell cycle compared with the untreated 
control group. In contrast, CUR-DMSO, MCM-41-CUR and MCM-41-NH2-CUR treatment 
caused marked increase in S and G2/M-phases of cell cycle leading to cell death (Fig. 12).  The 
G0/G1 phase significantly decreased from 65% for untreated control group to 36%, 30% and 
28% for CUR-DMSO, MCM-41-CUR and MCM-41-NH2-CUR respectively. Furthermore, a 
concomitant increased in S and G2/M phases was observed for CUR-DMSO (S= 35% and 
G2/M= 28%), MCM-41-CUR (S= 49% and G2/M= 22%) and MCM-41-NH2-CUR (S= 33% and 
G2/M= 39%) when compared with untreated control group (S= 27% and G2/M= 8%).  
To further investigate the link between cell cycle arrest and the mode of cell death, AnnexinV-
FITC/PI staining assay was used to confirm SCC25 cell death by apoptosis (Fig. 13). SCC25 
cells were treated with 15 μg/mL equivalent curcumin concentrations from four formulations 
along with respective control blank nanoparticles for 24 h. Treatment with CUR-DMEM, MCM-
41 and MCM-41-NH2 blank particles did not alter the apoptotic cell death and were comparable 
to untreated control cells. These results are similar to the in vitro cytotoxicity studies confirming 
the bio-inertness and biocompatibility of MSNs. On the contrary, CUR-DMSO, MCM-41-CUR 
and MCM-41-NH2-CUR significantly induced apoptosis in SCC25 cells compared with 
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untreated control cells. CUR-DMSO treated cells showed 9% and 90% of early apoptotic 
(AnnexinV-FITC+/PI−) and late apoptotic/early necrotic (AnnexinV-FITC+/PI+) populations 
respectively, compared to MCM-41-CUR (11% and 88%) and MCM-41-NH2-CUR (15% and 
82%) treated cells at 15 μg/mL dose for 24 h. These results indicate that both MCM-41-CUR and 
MCM-41-NH2-CUR had similar cell apoptosis which is on par compared with CUR-DMSO.  
3.7. ROS assay 
Curcumin is known to induce apoptosis by increasing the generation of ROS.
36
 Thus, we studied 
the effect of all the three formulations (CUR-DMSO, MCM-41-CUR and MCM-41-NH2-CUR) 
on generation of ROS at a single dose (15μg/mL) in a time dependent manner (Fig. 14). We have 
excluded CUR-DMEM due to lack of efficacy for inducing apoptosis. It was observed that, at 
equivalent dose, the ROS generation levels are MCM-41-NH2-CUR> MCM-41-CUR> CUR-
DMSO. This ROS helps to induce mitochondrial damage leading to apoptosis. In our study, 
CUR-DMSO, MCM-41-CUR and MCM-41-NH2-CUR treatment caused ROS generation 
mediated mitochondrial damage as revealed from reduction in MTT value and the AnnexinV-
FITC assay further confirm apoptosis in SCC25 cells.  
4. DISCUSSION 
In the current investigation, the effect of surface functionalization on anticancer activity was 
studied by encapsulating curcumin in MCM-41 type MSNs in SCC25 cell line. Positively 
charged, negatively charged and hydrophobic MSNs were synthesized to study this work. These 
nanoparticles were characterized using various techniques such as XRD, WXRD, nitrogen 
physiosorption, FTIR, Raman spectroscopy and further evaluated for their performance by 
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studying their in vitro release, in vitro cytotoxicity, cell uptake, silica content, flow cytometry 
and cell apoptosis. The XRD pattern revealed three well resolved diffraction peaks for MCM-41, 
MCM-41-NH2 and MCM-41-CH3 (Fig. 1A). The diffraction peak positions for MCM-41-NH2 
are observed to shift at a lower 2θ. This shift at lower 2θ is due to the solvent extraction method 
employed for the surfactant template removal resulting in decreased silanol condensation 
compared to that of calcination process used for the synthesis of MCM-41 and MCM-41-CH3.
27
 
WXRD study (Fig. 1B) conducted to confirm the crystalline nature of curcumin showed that 
MCM-41-CUR PM, MCM-41-NH2-CUR PM and MCM-41-CH3-CUR PM display diffraction 
peaks corresponding to pure curcumin indicating the crystalline nature of CUR in them. 
However, we cannot observe such peaks for MCM-41-CUR, MCM-41-NH2-CUR and MCM-41-
CH3-CUR materials suggesting that CUR is entrapped inside the nanopores with an amorphous 
nature.
32,33
 Nitrogen physiosorption studies (Fig. 3A, B) reveal the surface parameters of the 
MSNs synthesized with different surface chemistry and after encapsulating curcumin in them. 
The modified method for grafting amino groups on MCM-41 helps in attaining similar pore size 
as MCM-41. A small amount of the silica source (APTES) can replace the surfactants during the 
post-modification process starting from the as-synthesized MCM-41 resulting in decreased pore 
size.
28
 If the post-modification of amino groups starts from MCM-41 after removing the 
surfactants, the pores will be blocked (data not shown).
37
 The change in pore size of MCM-41-
CH3 is due to the presence of small amount of methyl groups in pore channels during the 
modification process. Our observation is consistent with previous reports on the hydrophobic 
modification of mesoporous materials after removing the surfactants, where the pore size is 
reduced by 0.25 – 0.65 nm.27,38 On encapsulating curcumin in these materials we can observe 
change in pore size, surface area and pore volume indicating successful loading of CUR inside 
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the nanopores. The successful surface modification on MCM-41 materials was confirmed by 
dispersing them in ether – water composition which showed that MCM-41 and MCM-41-NH2 
materials were totally dispersed in aqueous phase indicating their hydrophilic nature. On the 
other hand MCM-41-CH3 material was dispersed completely in organic phase displaying its 
hydrophobic nature. 
The peaks displayed by MCM-41 in FTIR analysis at 810, 1060, 1630 and 3745  cm
-1
 (Fig. 4A-
C) can be indexed to symmetric and asymmetric Si–O–Si stretching (s(Si-O-Si), a(Si-O-Si)), 
bending mode of physiosorbed water and to the isolated silanol ((O-H)) respectively.39,40 The 
peaks observed on amino modification at 2929, 1631 and 1518 cm
-1
 can be attributed to C–H 
stretching, N–H bending and N–H stretching vibrations of aminopropyl group anchored on the 
surface of MCM-41.
13,41,42
 The peaks observed after methyl modification at 2964 cm
-1
 which can 
be attributed to C–H vibration and band of peaks at 1255, 848 and 758 cm-1 attributed to Si-CH3 
of methyl group from TMCS.
38,43
 The sharp peak displayed by pure curcumin at 3507 cm
-1
 and a 
broad peak at 3293 cm
-1
 is attributed to –OH group vibrations without and with intermolecular 
hydrogen bonding, respectively.
44
 A new broad peak observed in MCM-41-CUR after 
encapsulating curcumin is due to intermolecular hydrogen bonding between isolated silanol and 
enolic hydroxyl group.
17
 The shift in the peak from 1506 cm
−1
 due to the (C=O), δ(CCC) and 
δ(CC=O) to 1513 cm−1 in case of MCM-41-CUR, MCM-41-NH2-CUR and MCM-41-CH3-CUR 
could be taken as an evidence of complex formation.
34
 To confirm the encapsulation of curcumin 
in MCM-41, Raman spectroscopy was performed (Fig. 5). Pure curcumin displays a sharp peak 
1633 cm
−1
 corresponding to (C=C) and (C=O) which is shifted to 1640 cm−1 in MCM-41-
CUR indicating strong interaction between enolic -OH of curcumin and silanol group of MCM-
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41.  The similar trend was observed for MCM-41-NH2-CUR and MCM-41-CH3-CUR wherein 
the enolic -OH of curcumin interacts with the silanol groups loacted on the interior surface of 
MCM-41-NH2 and MCM-41-CH3 materials. The successful encapsulation of curcumin in MCM-
41 materials is provided by the symmetric aromatic ring stretching vibrations (C-C ring) of 
curcumin at 1605 cm
−1
. The ratio of intensity of 1633 cm
−1
 peak to that of 1605 cm
−1
 peak is 
0.70 for pure curcumin. However, for MCM-41-CUR, MCM-41-NH2-CUR and MCM-41-CH3-
CUR the ratio of intensity of 1640 cm
−1
 peak to that of 1605 cm
−1
 peak is 1.05, 1.02 and 1.07 
respectively suggesting the aromatic ring is in the pores of MCM-41 materials.
34
 Thus Raman 
spectroscopy provided clear and distinct evidence of the curcumin encapsulation in MCM-41 
materials. DSC analysis (Fig. 6B, 7B) conducted for MCM-41-CUR PM, MCM-41-NH2-CUR 
PM and MCM-41-CH3-CUR PM samples displays a weak signal at 176C which corresponds 
with the sharp melting point peak for pure curcumin indicating the existence of curcumin’s 
crystalline state in their respective physical mixtures. However, no such peak is observed in case 
of in MCM-41-CUR, MCM-41-NH2-CUR and MCM-41-CH3-CUR samples indicating 
curcumin’s non-crystalline state and its successful loading as nano-sized aggregates in the pore 
channels of these MCM-41 materials.
45,46
 
The in vitro release studies (Fig. 8) demonstrate faster release of curcumin from MCM-41-CUR 
which could be attributed to the presence of curcumin as nano-sized aggregates in the pore 
channels of MCM-41. The comparative slower release of curcumin from MCM-41-NH2-CUR 
could be attributed to the APTES grafting on the surface which may impart relatively slight 
hydrophobicity owing to the aminopropyl chain of APTES leading to slower influx of 
dissolution media in the pore channels which would eventually delay the dissolution of 
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curcumin. Also, APTES grafting would impart some steric hindrance inhibiting the release of 
curcumin from the pore channels.
47
 This finding is in accordance with an earlier report using 
emodin as the drug molecule.
48
 The relatively slower curcumin release from MCM-41-CH3-CUR 
can be attributed to the poor wetting of the material owing to the hydrophobic methyl group on 
its surface reducing the interaction of encapsulated curcumin with the aqueous media.
25
 This 
hydrophobic modification results in very slow dissolution of drug resulting in slower release 
which is also supported by the TGA curve in Fig. 6A. Thus, surface modification by varying the 
surface charge and hydrophobicity plays an important role in modulating the curcumin release 
from MSNs. 
The in vitro cytotoxicity studies (Fig. 9) for CUR-DMEM displayed moderate cytotoxicity which 
could be due to reduced solubility of curcumin in aqueous medium (DMEM) as curcumin is 
hydrophobic and aqueous insoluble.
49
 CUR-DMSO showed a strong inhibitory effect however, 
this DMSO formulation has clinical limitation. The minimal cytotoxicity displayed by MCM-41-
CH3-CUR could be attributed to slow release of CUR from the nanoparticles because of poor 
wetting effect owing to its hydrophobic nature which is also evident from in vitro release study. 
The plausible reason behind higher cell inhibitory efficacy demonstrated by MCM-41-CUR and 
MCM-41-NH2-CUR could be due to enhanced release of curcumin from nanoparticles as 
supported by the in vitro dissolution studies. A comparison of MTT results showed greater cell 
inhibition by MCM-41-NH2-CUR than MCM-41-CUR at earlier time point (24 h and 48 h) 
which could be due to positive charge by -NH2 modification on the particle surface leading to 
higher endocytosis as reported by previous studies.
50-53
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Cell uptake studies (Fig. 10) showed higher uptake of curcumin from MCM-41-NH2-CUR owing 
to its positive charge which helps in electrostatic interaction with the negatively charged cell 
membrane leading to higher endocytosis. This result is in line with earlier studies which stated, 
positively charged nanocarriers mediated transport of CUR for effective anti-cancer therapy into 
the negatively charged cancer cell via enhanced permeation and retention (EPR) effect.
49
 The 
uptake of curcumin from negatively charged MCM-41-CUR suggests different pathways 
followed by these MSNs to exhibit their effect.  Silica content was measured (Fig. 11) to support 
the cell uptake studies which showed higher cell uptake of MCM-41-NH2-CUR at 4 h compared 
to MCM-41-CUR. However on further incubation at 24 h, the silica content decreased by 
approximately 40% for MCM-41-NH2-CUR while it remain unchanged for MCM-41-CUR. This 
result could be attributed to the lysosomal escape of positively charged nanoparticles after being 
internalized whereas high colocalization of negatively charged nanoparticles with lysosome 
similar to earlier report.
54
 
Cell cycle analysis (Fig. 12) was conducted on four formulations – CUR-DMEM, CUR-DMSO, 
MCM-41-CUR and MCM-41-NH2-CUR to understand their influence on cell cycle by treating 
with 15 μg/mL equivalent curcumin concentrations for 24 h. The data obtained suggests that 
CUR-DMSO slightly modulates S-phase but mainly affects the G2/M phase of cell cycle in 
SCC25 cells. On the other hand, MCM-41-CUR markedly affects both S and G2/M whereas 
MCM-41-NH2-CUR nanoparticles mildly impacts S-phase and significantly inhibiting G2/M 
phase. Our observation is in line with a previous study reporting CUR induces dose dependent S 
and G2/M cell cycle arrest in human cancer cells.
55,56
 The diverse effect of MCM-41-CUR and 
MCM-41-NH2-CUR could be attributed to their net negative and positive charges respectively 
but need further investigation. The predominant features of these current data suggests that, both 
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MCM-41-CUR and MCM-41-NH2-CUR nanoformulations are potent to deliver curcumin 
efficiently inside the cancer cells to execute their anticancer therapeutic effect which cannot be 
achieved by aqueous CUR-DMEM. 
AnnexinV-FITC/PI staining assay (Fig. 13) was used to investigate the link between cell cycle 
arrest and the mode of cell death for the four formulations – CUR-DMEM, CUR-DMSO, MCM-
41-CUR and MCM-41-NH2-CUR. MCM-41-CUR and MCM-41-NH2-CUR both displayed 
similar cell apoptosis which was on par with organic CUR-DMSO. The plausible reason for such 
similar activity by negatively and positively charged nanoparticles could be attributed to the in 
vitro release profile and cell uptake studies. MCM-41-CUR had low cellular uptake in SCC25 
cells but displayed faster in vitro release which could lead to higher CUR content in the cells to 
display its apoptotic activity. In the case of MCM-41-NH2-CUR, it had higher cellular uptake 
however the in vitro release was comparatively slower resulting in CUR content similar to that of 
MCM-41-CUR. ROS assay was studied (Fig. 14) to investigate if MCM-41-CUR and MCM-41-
NH2-CUR induces ROS generation by the releases curcumin. There are many reports supporting 
our data and stating that curcumin can generate ROS to damage mitochondria and apoptosis in a 
variety of cancer cell lines.
57-59
 These data further suggests that organic solvent free 
nanoparticles can display therapeutic efficacy similar to that of control group (using toxic 
organic solvent) which could have clinical implications in lab to bed side translational research. 
5. CONCLUSION 
Silica nanoparticles with different surface charge and hydrophobicity were synthesized and 
encapsulated with curcumin to evaluate its effect on cellular uptake and anticancer activity. It 
was observed that the encapsulation of curcumin in hydrophilic nanoparticles enhanced drug 
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release and cell cytotoxicity compared to the hydrophobic nanoparticles. Confocal miscroscopy 
and silica content studies showed higher cellular uptake of MCM-41-NH2-CUR compared to 
MCM-41-CUR. This is because of the electrostatic interaction between positively charged 
MCM-41-NH2-CUR and the negatively charged cancer cells. However, the cell cycle analysis 
and Annexin V-FITC/ PI assay demonstrated similar anticancer activity by both MCM-41-CUR 
and MCM-41-NH2-CUR. The similar anticancer activity displayed by positively and negatively 
charged MSNs could be attributed to their in vitro release behaviour and cellular uptake. Thus, in 
our study, the surface charge variation resulted in similar anticancer activity for curcumin. 
Moreover, the findings from this study suggests that organic solvent free nanoparticles as 
promising carriers for gaining higher therapeutic efficacy which could be useful for clinical 
implications from lab to bed side translational research.  
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Figure 1. (A) XRD patterns of MCM-41 materials with and without Curcumin loading. (B) 
WXRD patterns of MCM-41 materials with and without Curcumin loading and physical 
mixtures of curcumin with unfunctionalized and functionalized MCM-41 materials. 
 
 
Figure 2. Transmission Electron Microscopy (TEM) image of MCM-41(a), MCM-41-NH2 (b) 
and MCM-41-CH3 (c) materials. 
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Figure 3. A) N2 adsorption/desorption isotherms and B) BJH pore-size distribution plot for 
unfunctionalized and functionalized MCM-41 materials with and without Curcumin loading. C) 
Digital image of a) MCM-41, b) MCM-41-NH2 and c) MCM-41-CH3 demonstrating the 
hydrophobicity of materials by dispersing them in organic (ether) – aqueous (water) 
composition. 
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Figure 4. FTIR spectra of unfunctionalized and functionalized MCM-41 materials with and 
without curcumin loading. 
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Figure 5. Raman spectra of pure curcumin and functionalized MCM-41 materials encapsulated 
with curcumin. 
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Figure 6. TGA (A) and DSC (B) curves of unfunctionalized and functionalized MCM-41 
materials with and without curcumin loading. 
 
 
Figure 7. TGA (A) and DSC (B) curves of physical mixtures of curcumin with unfunctionalized 
and functionalized MCM-41 materials. 
Chapter 6 
Effect of Surface Functionality of Silica Nanoparticles on Cellular Uptake and Cytotoxicity 
 
108 
 
 
Figure 8. In vitro release of pure Curcumin and Curcumin loaded in MCM-41-CUR, MCM-41-
NH2-CUR and MCM-41-CH3-CUR materials in 0.5% SLS. 
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Figure 9. In vitro cytotoxicity of pure curcumin, MCM-41-CUR, MCM-41-NH2-CUR and 
MCM-41-CH3-CUR in SCC-25 cell line after 24, 48 and 72h with curcumin equivalent dose of 
15 ppm, 30 ppm and 45 ppm respectively. 
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Figure 10. Confocal microscopy images of SCC25 cells without any treatment as control (CTL), 
CUR-DMEM, CUR-DMSO, MCM-41-CUR and MCM-41-NH2-CUR. Blue signal denotes the 
nuclei stained with DAPI and green fluorescence arises from curcumin. Scale bar represents 20 
m. 
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Figure 11. Si concentrations determined by ICP-OES for MCM-41-CUR and MCM-41-NH2-
CUR endocytosed in SCC25 cell line after 4 and 24 h. 
 
Figure 12. Cell cycle analysis of control (CTL), CUR-DMEM, CUR-DMSO, MCM-41-CUR 
and MCM-41-NH2-CUR in SCC25 cells after 24 hrs. 
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Figure 13. Cell apoptotic studies of control (CTL), CUR-DMEM, CUR-DMSO, MCM-41-CUR 
and MCM-41-NH2-CUR with respective control groups in SCC25 cells. 
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Figure 14. ROS assay of CUR-DMSO, MCM-41-CUR and MCM-41-NH2-CUR. 
 
Scheme 1. Schematic representation comparing the in vitro drug release of curcumin from 
MCM-41-CUR, MCM-41-NH2-CUR and MCM-41-CH3-CUR samples and its cell cytotoxicity 
performance in SCC25 cell line. Inset represents the binding of curcumin to the interior pore wall 
of MCM-41, MCM-41-NH2 and MCM-41-CH3 samples.  Free drug is represented in yellow 
color. Inset shows the binding of CUR in MCM-41. 
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Table 1. Physicochemical properties of unfunctionalized and functionalized MCM-41 materials 
with and without curcumin loading  
Sample a (nm) P (nm) SBET  (m
2
/g) Vp  (cm
3
/g) Z.P. (mV) 
MCM-41 4.19 2.17 995 0.79 -36.4 ± 1.42 
MCM-41-NH2 4.92 2.10 932 0.74 36.3 ± 2.52 
MCM-41-CH3 4.61 1.80 835 0.61 -18.2 ± 1.40 
MCM-41-CUR 4.30 2.10 450 0.44 -35.27 ± 0.40 
MCM-41-NH2-CUR 4.90 1.91 407 0.39 23.6 ± 0.92 
MCM-41-CH3-CUR 4.61 1.73 343 0.33 -24.3 ± 1.00 
Note: a=cell dimension; SBET = BET surface area; Vp = pore volume; P = pore size; Z.P. = Zeta 
potential.  
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Mesoporous silica nanoparticles (MCM-41) were used as a carrier system to study the 
influence of surface charge and hydrophobicity on solubility and in-vitro drug release 
behavior of Griseofulvin, a potent antifungal drug with low water solubility. Surface charge 
modification showed enhancement in both solubility and drug release of griseofulvin 
compared to the hydrophobic modification due to the poor wetting effect by the hydrophobic 
groups grafted on MCM-41 nanoparticles. Thus, the surface functionalization on MCM-41 is 
found to have significant effect on griseofulvin’s in vitro release and solubility 
 
Chapter 7 is included as it appears in Journal of Colloid and Interface Science, 2014,434, 
218-225. 
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Conclusions and Future Directions 
 
8.1 Conclusions 
 
Hydrophobic drugs pose a major disadvantage of low aqueous solubility which lowers its 
bioavailability and delays their clinical applications. Hence, enhancing the solubility of such 
hydrophobic drugs is of great importance. Reducing the drug particle size to nanoscale is the 
preferred approach to enhance the solubility. However, with the existing strategies, it is difficult to 
reduce the drug particle size below 20 nm, a regime where drastic increase in the solubility is 
expected based on Ostwald-Freundlich equation. Mesoporous Silica Nanoparticles (MSNs) have 
been looked at to provide solution in solubility enhancement. However, one needs to control the 
pore size of MSNs precisely at angstrom scale so that they can find an optimized pore size for a 
given drug molecule which would display highest solubility.  
  
The first major contribution of this work is successful development of a novel Vacuum-assisted 
Vapour Deposition (VVD) method to control the pore size of MSNs at angstrom scale. The pore 
size was controlled in the range of 2 – 4 Å and 4 – 6 Å using tetraethoxyorthosilicate and 
tetramethoxyorthosilicate as silica precursors respectively. The advantage of VVD method is that, it 
can control the pore size of MSNs in a stepwise manner with the same angstrom precision. This fine 
pore size control was not achievable with earlier methods reported in the literature. The series of 
pore size reduced MSNs were characterised using X-ray diffraction (XRD), Nitrogen 
adsorption/desorption isotherms and Fourier Transformed Infrared Spectroscopy (FTIR) to evaluate 
its structural characteristics after conducting VVD process for 3 cycles. It was found that, the 
ordered structure of MSNs is retained even after 3 VVD cycles demonstrating the advantage of this 
novel method. A pore size – solubility correlation was established by encapsulating a hydrophobic 
anticancer drug, Curcumin in the series of pore size reduced MSNs. An optimized pore size was 
found out which displayed highest solubility. This novel VVD method provides a general strategy 
to find an optimized pore size for a given drug molecule which would help in enhancing their 
solubility. 
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Effective cancer treatment requires the anticancer drug to reach its target and kill the cancer cells. 
However, the anticancer drugs are hydrophobic with low aqueous solubility and hence we need to 
increase the drug solubility. Also, we need an appropriate drug carrier system to deliver the 
anticancer drug to its target. The second major contribution of this work is to enhance the 
cytotoxicity of curcumin by encapsulating it in MSN. Curcumin was encapsulated in MSNs which 
helped in increasing the solubility, drug release and cytotoxicity compared to the pure drug. The 
cytotoxicity studies were performed in skin cancer cell line, SCC-25 as cancer model. It was clearly 
demonstrated that the curcumin encapsulated MSNs enhanced the cytotoxicity compared to the pure 
drug. Thus, MSNs performed dual role of enhancing the drug solubility and as drug carrier system 
to cancer cells. 
 
Among the several properties of MSNs, ease of surface functionalization is one of the most 
important criteria which have enticed researchers for its diverse applications. More specifically, it 
plays a vital role in the field of pharmaceutical drug delivery to enhance the properties such as 
cellular uptake, targetability and stimuli responsive drug release to name a few by encapsulating 
drug molecules in MSNs. However, the effect of surface functionalization needs to be carefully 
studied to identify if it significantly enhances the applicability. The third major contribution of this 
work is to investigating the influence of surface functionalization on drug solubility, drug release 
and cytotoxicity. Effect of surface charge and hydrophobicity was studied by comparing MSNs with 
positive charge (hydrophilic nature), negative charge (hydrophilic nature) and negative charge 
(hydrophobic nature) using two model hydrophobic drug molecules – Curcumin and Griseofulvin. 
It was found that the negatively charged hydrophilic MSNs improved the drug solubility and drug 
release for both the drugs compared to the others. Hydrophobic MSNs displayed the slowest drug 
release profile. Cytotoxicity studies conducted using MTT assay showed that negatively and 
positively charged MSNs both had similar cytotoxicity. On further investigation performed using 
cell cycle analysis and cell apoptosis, it was observed that, the negatively charged (hydrophilic 
nature) MSNs show slightly better performance compared to the positively charged (hydrophilic 
nature). Thus, the general understanding of designing positively charged drug carrier system does 
not hold true and it should be treated on a case-by-case basis.  
 
8.2 Recommendations 
 
In recent years, a lot of attention is given to modify and design the applicability of MSNs especially 
in drug delivery. The field of drug delivery faces critical issues of enhancing solubility of 
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hydrophobic drugs and designing an ideal carrier system which can reach its target site. This thesis 
focuses on the efficiency of inorganic MSNs to resolve these issues. We have demonstrated the 
potential of MSNs to enhance solubility and cytotoxicity of the anticancer drug. However, there are 
few aspects which further need to be explored.  
 
In this thesis we determined an optimized MSN pore size for curcumin as drug molecule. The VVD 
process should be applied to few other hydrophobic drug molecules to showcase its advantage and 
making it a more general approach to enhance solubility. 
 
Apart from anticancer drug molecules, biomolecules such as siRNA are reported to be more 
effective in treating cancers. Based on the VVD process, an optimized MSN pore size should be 
determined for a given biomolecules and its efficiency needs to be evaluated. This would further 
expand the applicability of MSNs. 
 
The cytotoxicity enhancement study demonstrated negatively charged MSNs to show slightly better 
cytotoxicity compared to positively charged MSNs. However, this study was performed using SCC-
25 cancer cell line. It is recommended to perform in-vivo experiments using mice as animal model. 
The pharmacokinetics study should be conducted to evaluate the performance of both positively and 
negatively charged MSNs compared to pure drug. Also, tumor inhibition efficacy of anticancer drug 
encapsulated MSNs should be tested on mice models by comparing it with pure drug or commercial 
product. 
 
In order to prove the completeness of the study, it would be highly recommended if the anticancer 
drug encapsulated MSNs can be formulated as a tablet or capsule dosage form.  
 
In summary, we successfully developed VVD method for controlling the MSN pore size at 
angstrom scale and demonstrated its application for solubility enhancement. Further we studied the 
influence of surface functionalization and have some important findings which would give new 
approach in designing carrier systems. This work could be of interest for vast audience of chemists 
and material scientists in various fields of catalysis, nanomedicine and biomedical engineering. 
 
